Online citations, reference lists, and bibliographies.

2015 American Thyroid Association Management Guidelines For Adult Patients With Thyroid Nodules And Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force On Thyroid Nodules And Differentiated Thyroid Cancer.

B Haugen, Erik K. Alexander, Keith C Bible, Gerard M. Doherty, Susan J. Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W. Randolph, Anna M Sawka, Martin Jean Schlumberger, Kathryn G. Schuff, Steven I Sherman, Julie Ann Sosa, David L Steward, Robert Michael Tuttle, Léonard Wartofsky
Published 2016 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. METHODS The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members. RESULTS The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research. CONCLUSIONS We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.
This paper references
Overall and causespecific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer
BM Barney (2011)
10.4158/ep.14.6.764
Risk-adapted management of thyroid cancer.
Robert Michael Tuttle (2008)
10.1016/j.ecl.2008.02.007
An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
Anna M Sawka (2008)
10.1210/jc.2005-2009
Second primary cancers in thyroid cancer patients: a multinational record linkage study.
Thekkepat C. Sandeep (2006)
Application of postsurgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma
A Vaisman (2010)
Patient satisfaction with decisionmaking for breast cancer therapy
SM Weiss (1996)
10.1097/RLU.0b013e3181e9f917
Role of Tc-99m Pertechnetate for Remnant Scintigraphy Post-Thyroidectomy
Sherman S H Kueh (2010)
10.1007/s00259-010-1608-9
On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer
Paolo Zanotti-Fregonara (2010)
10.1111/j.1365-2265.2012.04342.x
Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Fernanda Vaisman (2012)
10.1016/j.ejso.2010.11.005
Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion.
Chris O’Neill (2011)
10.1210/jc.2006-0723
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Martin Jean Schlumberger (2007)
10.1016/s0025-6196(12)61170-7
Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome.
Michael D. Brennan (1991)
10.1002/14651858.CD006988.pub2
Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.
Chao Ma (2009)
10.1016/j.surg.2010.09.029
Routine second-opinion cytopathology review of thyroid fine needle aspiration biopsies reduces diagnostic thyroidectomy.
Tomer Davidov (2010)
10.1002/lary.21097
Early versus late injection medialization for unilateral vocal cord paralysis.
Aaron D Friedman (2010)
10.1080/078538902321117760
Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer
Nayahmka J McGriff (2002)
10.4174/JKSS.2010.78.2.82
Risk Factors of Lymph Node Metastasis in Papillary Thyroid Microcarcinoma
Nam Seop Lee (2010)
10.1016/j.ejso.2006.12.016
[Papillary thyroid microcarcinoma. Long-term outcome in 587 cases compared with published data].
Maria Rosa Pelizzo (2007)
10.1001/jama.1975.03260100039017
Thyroid nodularity in children.
Marvin L. Rallison (1975)
10.1210/jcem.75.3.1517360
The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.
Naguib A. Samaan (1992)
10.1159/000334218
Variability in the Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: Sources and Recommendations
N Paul Ohori (2011)
10.1148/radiol.2473070944
Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study.
Won-Jin Moon (2008)
10.1007/BF03349472
Serum thyroglobulin in patients undergoing subtotal thyroidectomy for toxic and nontoxic goiter
Ulla Feldt-Rasmussen (1982)
10.1016/j.jvoice.2008.12.005
The role of experience on judgments of dysphonia.
Tanya L. Eadie (2010)
10.1210/jc.2009-1567
Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
Won Gu Kim (2010)
Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Kunihiro Nakada (2005)
Second primary Page 363 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
S Subramanian (2007)
Persistent disease and recurrence in differentiated thyroid cancer patients with Page 328 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y
C Nascimento (2011)
10.1210/jc.2006-2566
Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer.
Guido C. J. Hovens (2007)
10.1002/hed.21462
Ultrasonographic screening for occult thyroid cancer.
Anthony Po Wing Yuen (2011)
10.1016/j.otohns.2005.06.007
Efficacy of Thyroid Hormone Suppression for Benign Thyroid Nodules: Meta-Analysis of Randomized Trials
Matthew T. Sdano (2005)
10.1210/jc.2013-2292
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.
Marina N Nikiforova (2013)
Differentiated thyroid cancer long-term impact of initial therapy.
Ernest L. Mazzaferri (1995)
10.2214/AJR.08.1820
Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone?
John A. Bonavita (2009)
10.1093/qjmed/hcl121
The predictive value of ultrasound findings in the management of thyroid nodules.
Carlo Cappelli (2006)
10.1097/01.sla.0000217685.85467.2d
Radiofrequency Ablation and Percutaneous Ethanol Injection Treatment for Recurrent Local and Distant Well-Differentiated Thyroid Carcinoma
Jack M. Monchik (2006)
10.1089/thy.2008.0160
Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients.
Umberto Crocetti (2008)
Post I-131 ATA THYROID NODULE/DTC GUIDELINES 119 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution
PW Souza Rosario (2004)
A 2010 Cribriform-morular variant of papillary thyroid carcino 110 HAUGEN ET AL. ma—cytological and immunocytochemical findings of 18 cases
M Hirokawa (2010)
Diagnostic 131-iodine whole-body scan 122 HAUGEN ET AL. may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment
F Pacini (2002)
ATA THYROID NODULE/DTC GUIDELINES
M Toubeau (2004)
Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic 128 HAUGEN ET AL. radioiodine whole body scan
M Chao (2010)
Patient satisfaction with decisionmaking for breast cancer therapy
SM Weiss (1996)
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent nonanaplastic non-medullary thyroid cancer
PB Romesser (2014)
A systematic review of randomized controlled trials for man 132 HAUGEN ET AL. agement of persistent post-treatment fatigue in thyroid cancer survivors
J To (2014)
Percutaneous ultrasoundguided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer
E Papini (2013)
10.1089/thy.2009.1611
The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.
Douglas van Nostrand (2009)
Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer.
Aban M Samuel (1998)
10.1007/s00259-010-1536-8
EANM procedure guidelines for therapy of benign thyroid disease
Marcel P. M. Stokkel (2010)
10.2214/AJR.08.1218
Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma.
Ka Kit Wong (2008)
10.1210/jc.2003-030122
Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays.
Carol M. Preissner (2003)
10.2174/1568008013341550
Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research.
Nicholas J. Sarlis (2001)
10.1089/105072501316973145
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients.
Furio Pacini (2001)
10.1210/jcem.84.12.6190
Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Pei-Wen Wang (1999)
10.1111/j.1365-2265.2011.04162.x
Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment.
Mubashir Mulla (2012)
10.1089/thy.2010.0174
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.
Michael Rivera (2010)
10.1200/JCO.2007.15.9566
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E. W. Cohen (2008)
10.3892/ijo.25.6.1729
The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma.
Ilya Sedliarou (2004)
10.1007/BF00620474
High or low dose radioiodine ablation of thyroid remnants?
Hans Creutzig (2004)
10.1007/s00268-010-0571-8
Central Lymph Node Metastasis as a Predictor of Lateral Node Involvement in Papillary Thyroid Carcinoma: Reply to Letter
Gui-zhou Xiao (2010)
A 2010 The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging
W Jentzen (2010)
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
Martin Jean Schlumberger (1996)
10.1016/j.surg.2012.12.008
Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
Ji In Lee (2013)
The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer.
Richard S. Benua (1962)
10.1089/thy.2010.0026
Fine-needle biopsy should be performed in solid hypoechoic thyroid nodules greater than one centimeter even in the absence of suspicious ultrasonographic characteristics.
Pedro Weslley Rosario (2010)
10.2967/jnumed.108.052746
Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation
Daniela Schmidt (2009)
10.1210/jc.2012-2369
Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma.
Min Ji Jeon (2013)
A 2010 Cribriform-morular variant of papillary thyroid carcino 110 HAUGEN ET AL. ma—cytological and immunocytochemical findings of 18 cases
M Hirokawa (2010)
10.1210/jcem.84.3.5527
Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma.
S S Koong (1999)
10.1210/jc.2011-3330
Update in utility of secondary node dissection for papillary thyroid cancer.
David L Steward (2012)
10.1001/archoto.2011.215
Therapeutic sialendoscopy for the management of radioiodine sialadenitis.
Brandon L. Prendes (2012)
10.1111/j.1365-2265.2006.02685.x
Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Karen A. Heemstra (2006)
18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results.
Lioe-Fee de Geus-Oei (2006)
10.1111/j.1365-2265.1994.tb02785.x
Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules.
Giovanna Verde (1994)
10.1210/jc.2014-3825
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.
David Viola (2015)
Early versus late injection medialization for unilateral vocal cord paralysis. Laryngoscope 120:2042–2046
AD Friedman (2010)
10.1177/019459989411100419
Evaluation and Treatment of the Unilateral Paralyzed Vocal Fold
Harry B. Neel (1994)
10.1530/eje.0.1500133
Advances in diagnostic practices affect thyroid cancer incidence in France.
Laurence Leenhardt (2004)
10.1007/978-3-540-47648-1_2238
Follicular carcinoma.
Kaarle O. Franssila (1985)
Is (18)Ffluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 22:165–172
D Deandreis (2012)
10.1210/jc.2006-1345
131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review.
Allan Hackshaw (2007)
10.1016/S0039-6060(98)70036-4
Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy.
Laura E. Sanders (1998)
10.1007/s00423-013-1152-8
Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES)
Juan J. Sancho (2013)
10.1002/hed.21214
Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma.
Luca Giovanella (2009)
10.1210/jc.2008-2313
Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer.
Nicolas Aide (2009)
10.1016/S0039-6060(03)00424-0
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer.
Maria A Kouvaraki (2003)
Percutaneous ultrasoundguided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer
E Papini (2013)
Serum thyroglobulin in the followup of patients with treated differentiated thyroid cancer
M Ozata (1994)
10.1007/s00268-008-9588-7
Diagnostic Accuracy of CT and Ultrasonography for Evaluating Metastatic Cervical Lymph Nodes in Patients with Thyroid Cancer
Ji Eun Ahn (2008)
10.1016/j.ijrobp.2008.09.023
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment.
David L. Schwartz (2009)
Early versus late injection medialization for unilateral vocal cord paralysis. Laryngoscope 120:2042–2046
AD Friedman (2010)
Utility of the radioiodine whole-body retention at 48 hours for Page 356 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
D Van Nostrand (2009)
10.1111/j.1365-2265.2008.03424.x
Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
David Taïeb (2009)
10.1002/dc.21309
Cribriform-morular variant of papillary thyroid carcinoma--cytological and immunocytochemical findings of 18 cases.
Mitsuyoshi Hirokawa (2010)
10.1210/jc.2014-1098
Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy.
Giorgio Grani (2014)
10.1210/jc.2012-1169
Skeletal-related events due to bone metastases from differentiated thyroid cancer.
Azeez Farooki (2012)
10.1016/j.jvir.2013.02.001
Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma.
Jeffrey P. Guenette (2013)
10.1210/jc.2013-2383
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iňigo Landa (2013)
A systematic review of randomized controlled trials for man 132 HAUGEN ET AL. agement of persistent post-treatment fatigue in thyroid cancer survivors
J To (2014)
10.1196/annals.1318.024
Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects.
Diane Li (2004)
10.1001/jama.281.9.835
Quality assurance in molecular genetic testing laboratories.
Margaret M Mcgovern (1999)
10.1542/peds.2018-3063
Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer
Gary L. Francis (2018)
Recurrent nerve palsy after thyroid operations--principal nerve identification and a literature review.
Gerhard R. Jatzko (1994)
10.1155/2013/769473
Long-Term Results after Treatment of Very Low-, Low-, and High-Risk Thyroid Cancers in a Combined Setting of Thyroidectomy and Radio Ablation Therapy in Euthyroidism
Nikos Emmanouilidis (2013)
10.1016/j.jamcollsurg.2003.11.012
Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Julio C Furlan (2004)
10.1245/s10434-013-3428-1
Oncologic Outcomes After Completion Thyroidectomy for Patients with Well-Differentiated Thyroid Carcinoma
Brian R. Untch (2013)
10.1002/cncr.22956
Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Elliot Sampson (2007)
10.1111/j.1365-2265.2008.03222.x
A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.
Anna M Sawka (2008)
10.1210/jcem.86.8.7719
131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study.
Claudia Ceccarelli (2001)
10.1007/s12020-010-9339-z
Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma
Jordi Lluís Reverter (2010)
10.1056/NEJMcp010145
Clinical practice. Subclinical hyperthyroidism.
Toft Ad (2001)
10.1089/thy.2015.0104
Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?
Ian Ganly (2015)
10.1016/S0748-7983(97)92292-7
The dynamics of serum thyroglobulin elimination from the body after thyroid surgery.
Marko Hocevar (1997)
10.1002/hed.21371
Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Alon Vaisman (2010)
10.1002/14651858.CD008302.pub2
Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Chao Ma (2010)
10.1002/lary.20236
Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone.
Edward James Chisholm (2009)
10.1111/his.12246
Poorly differentiated thyroid carcinomas: application of the Turin proposal provides prognostic results similar to those from the assessment of high-grade features.
Viviane Gnemmi (2014)
10.1097/00005537-200301000-00014
Predictive value of serum thyroglobulin after surgery for thyroid carcinoma.
Francis T. Hall (2003)
10.1530/eje.0.1500105
Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.
Martin Jean Schlumberger (2004)
10.1089/thy.2012.0611
Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma.
Ching-Jung Hsieh (2014)
10.1007/BF00353765
Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer
Georg F. W. Scheumann (2004)
10.1053/otot.2002.36442
Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations.
Meyer Friedman (1990)
10.1007/s00063-010-1011-9
Epidemiologie, Pathophysiologie, leitliniengerechte Diagnostik und Therapie des Schilddrüsenknotens
Ralf Paschke (2010)
Impact of initial surgical treatment on Page 295 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Duren (2000)
BRAF mutation and p27 kip1 expression in papillary carcinomas of the thyroid
V Rodolico (2007)
10.4158/EP.1.1.9
Fine-needle aspiration biopsy: use in diagnosis and management of pediatric thyroid diseases.
H. Gharib (1995)
An expanded view of risk-group definition in differentiated thyroid carcinoma.
Blake Cady (1988)
Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma.
S. V. Hilts (1979)
10.1067/msy.2001.118370
Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis.
Nestor F. Esnaola (2001)
10.4082/KJFM.2010.31.2.87
Screening of Thyroid Cancer and Management of Thyroid Incidentaloma
Jung Jin Cho (2010)
10.1148/radiol.12112108
Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Yasuhiro Maruoka (2012)
10.1089/thy.1997.7.265
Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma.
Ernest L. Mazzaferri (1997)
10.1210/jc.85.3.1107
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
Wenli Wang (2000)
10.1245/s10434-010-1361-0
Electronic Synoptic Operative Reporting for Thyroid Surgery using an Electronic Data Management System: Potential for Prospective Multicenter Data Collection
Narayanan Gopalakrishna Iyer (2010)
10.1200/JCO.2008.16.3279
Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson (2008)
Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large Page 350 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
M Shargorodsky (2006)
10.1089/thy.2000.10.573
Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
Vahab Fatourechi (2000)
10.1210/jc.2002-021925
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
Furio Pacini (2003)
10.1002/cncr.21739
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
David H. Hiltzik (2006)
10.1007/s00259-008-0761-x
EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy
Michael Lassmann (2008)
Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral Page 307 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Raffaelli (2012)
Lowrisk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature
L Lamartina (2015)
Riskadapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156:1579–1588
A Ebina (2014)
10.1373/clinchem.2008.117614
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.
Andrea Rita Horváth (2009)
Calsolari MR 2014 Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid 24:533–536
PW Rosario (2014)
10.1007/s00268-010-0528-y
Central Lymph Node Metastasis: Is It a Reliable Indicator of Node Involvement in Papillary Thyroid Carcinoma? Letter to the Editor
P. V. Pradeep (2010)
Prognostic value of the tall cell variety of papillary cancer of the thyroid
Alfredo Moreno-Egea (1993)
10.1016/s1077-9108(08)79032-7
Diagnostic Terminology and Morphologic Criteria for Cytologic Diagnosis of Thyroid Lesions: A Synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference
Stephen Spencer Raab (2009)
10.1016/0002-9343(81)90573-8
Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients.
Ernest L. Mazzaferri (1981)
10.1067/msy.2099.101431
Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome.
Brian C Singh (1999)
10.1016/j.surg.2011.09.007
The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer.
Iain J Nixon (2011)
10.1089/thy.2011.2107.ed1
Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer.
Furio Pacini (2011)
10.1210/jc.86.11.5148
Clinical case seminar: Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration
Milena Braga (2001)
10.1016/j.surg.2007.08.012
The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size.
Kelly L. Mccoy (2007)
10.1089/thy.2010.1645
Considerations for personalized surgery in patients with papillary thyroid cancer.
Ralph P Tufano (2010)
10.1089/thy.2010.0048
Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule.
Antonella Camera (2010)
10.1210/jcem.79.1.8027262
Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
Metin Ozata (1994)
10.1016/j.surg.2013.06.040
The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer.
Kathleen O'Connell (2013)
Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 119:1135–1139
EJ Chisholm (2009)
Imageguided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma
JP Guenette (2013)
10.1136/adc.85.4.313
Fine needle aspiration biopsy of thyroid nodules
I S Arda (2001)
10.1007/s00761-010-1868-9
Tumortyp- und tumorstadienorientiertes chirurgisches Konzept bei Karzinomen der Schilddrüse
Henning Dralle (2010)
10.1002/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0
Dose response evaluation of adriamycin in human neoplasia.
Robert M. O'bryan (1977)
10.1097/CCO.0b013e32835a9ab1
Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer
Luca Giovanella (2013)
10.1016/j.ecl.2008.02.008
Follow up approaches in thyroid cancer: a risk adapted paradigm.
Robert Michael Tuttle (2008)
10.1001/jamainternmed.2013.9245
Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study.
Rebecca Smith‐Bindman (2013)
The benefits and risks of I-131 therapy in patients with welldifferentiated thyroid cancer
D Van Nostrand (2009)
10.1016/j.ejso.2003.08.006
Comparison of completion thyroidectomy and primary surgery for differentiated thyroid carcinoma.
Erhan Erdem (2003)
Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Robert Michael Tuttle (2006)
10.1046/j.1365-2273.2002.00559.x
The quality of life impact of dysphonia.
Janet A Wilson (2002)
10.1210/jc.2010-1500
Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values.
Richard T. Kloos (2010)
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
George Sgouros (2004)
10.1089/thy.2009.0403
Radioiodine accumulation in a large adnexal cystadenofibroma.
Omer Turker (2010)
10.1001/archsurg.133.4.419
Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment.
Laura E. Sanders (1998)
10.1002/cncr.22912
BRAFV600E mutation and p27kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases
Vito Rodolico (2007)
10.1007/s00268-004-7643-6
Value of the Cervical Compartments in the Surgical Treatment of Papillary Thyroid Carcinoma
Apostolos Goropoulos (2004)
10.1245/s10434-011-1619-1
Inoperable Symptomatic Recurrent Thyroid Cancers: Preliminary Result of Radiofrequency Ablation
Ko Woon Park (2011)
10.1515/CCLM.2005.142
Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma
Luca Giovanella (2005)
10.1089/cbr.2000.15.211
Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Giuliano Mariani (2000)
10.1056/NEJMoa1209288
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho (2013)
10.2967/jnumed.108.052399
Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
Libo Chen (2008)
10.4158/EP.14.6.764
Risk-Adapted Management of Thyroid Cancer
Tuttle Rm (2008)
A 2014 BRAF(V600E) Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients
Y Ito (2014)
10.1016/j.surg.2012.08.034
Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Tihana Ibrahimpašić (2012)
10.1210/jc.2011-0305
Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH
Hernán Tala (2011)
10.1097/PAS.0b013e3180309e6a
Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach
Marco Volante (2007)
10.1007/978-0-387-87666-5_6
Follicular Neoplasm, Hürthle Cell Type/Suspicious for a Follicular Neoplasm, Hürthle Cell Type
William C Faquin (2010)
10.1001/archotol.130.1.110
Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes.
Tracy S. Wang (2004)
10.1677/ERC-10-0071
Dosimetry and thyroid cancer: the individual dosage of radioiodine.
Michael Lassmann (2010)
10.2967/jnumed.107.049072
Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal
Robert Michael Tuttle (2008)
10.1007/s00259-007-0660-6
The diagnostic value of 124I-PET in patients with differentiated thyroid cancer
Ha T. T. Phan (2007)
Prevalence and causes of dysphonia in a large treatmentseeking population
SM Cohen (2012)
10.1159/000320856
Cytologic Characteristics and β-Catenin Immunocytochemistry on Smear Slide of Cribriform-Morular Variant of Papillary Thyroid Carcinoma
Ja Seung Koo (2010)
10.1530/eje.0.1480589
Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
K M van Tol (2003)
10.1002/cncy.20029
The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference.
Ritu Nayar (2009)
10.1210/jc.2010-2695
Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Pasqualino Malandrino (2011)
10.1002/lary.20617
Survival impact of treatment options for papillary microcarcinoma of the thyroid.
Harrison Lin (2009)
10.1089/thy.2012.0520
Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
Roger T. Anderson (2013)
Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Robert Dorn (2003)
10.1007/s00104-009-1883-9
Kalzitoninbestimmung zur Frühdiagnose des medullären Schilddrüsenkarzinoms
Wolfram Karges (2009)
10.1089/105072503321669875
An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid.
Yasuhiro Ito (2003)
10.5555/uri:pii:0039606094903042
Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma.
Douglas S. Tyler (1994)
10.1210/jc.2011-0356
Reduction of Thyroid Nodule Volume by Levothyroxine and Iodine Alone and in Combination: A Randomized, Placebo-Controlled Trial
Martin Grussendorf (2011)
10.3121/cmr.2010.881
Thyroxine Suppression Therapy For Benign, Non-Functioning Solitary Thyroid Nodules: A Quality-Effects Meta-Analysis
Altayyeb Yousef (2010)
10.1530/EJE-12-0405
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Tatiana C. Schneider (2012)
10.1001/archsurg.1996.01430140077021
Small carcinomas of the thyroid. A long-term follow-up of 867 patients.
Shiro Noguchi (1996)
10.1089/thy.2010.1626
Thyroid surgery and surgeons: the common interest.
John H. Yim (2010)
Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.
Massimo Eugenio Dottorini (1995)
10.1016/S0039-6060(03)00384-2
A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period.
Iwao Sugitani (2004)
10.1210/jc.2012-1083
Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis.
D Scott Mcleod (2012)
10.1089/thy.2012.0156
Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis.
Juan P. Brito (2013)
10.1172/JCI102630
The urinary excretion and thyroid uptake of iodine in renal disease.
William Perry (1952)
10.1089/thy.2009.0073
Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young.
Ja Seung Koo (2009)
10.1089/thy.2009.1608
Advances in ultrasound for the diagnosis and management of thyroid cancer.
Jennifer A. Sipos (2009)
10.1089/thy.2010.0003
Hypothyroidism in pregnancy: do guidelines alter practice?
Elizabeth N Pearce (2010)
10.1089/thy.2009.0438
Simultaneous metastatic papillary thyroid carcinoma and carcinoid of the small intestine in the cervical lymph node group.
Konstantinos Markou (2010)
10.1016/j.surg.2007.09.021
Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer.
Kelly L. Mccoy (2007)
Changes in risk factors and Tumor Node Metastasis Page 280 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
H Karga (2011)
10.1089/thy.2009.1609
Lessons from mouse models of thyroid cancer.
Caroline S Kim (2009)
10.1001/jama.295.18.2164
Increasing incidence of thyroid cancer in the United States, 1973-2002.
Louise Davies (2006)
10.1046/j.1365-2168.1998.00510.x
Pattern of lymph node metastases in papillary thyroid carcinoma.
Oliver Gimm (1998)
10.3348/kjr.2012.13.2.117
Radiofrequency Ablation of Benign Thyroid Nodules and Recurrent Thyroid Cancers: Consensus Statement and Recommendations
Dong Gyu Na (2012)
10.1210/jcem.87.4.8338
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Ernest L. Mazzaferri (2002)
10.5555/uri:pii:0039606093903214
Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.
Ian D. Hay (1993)
Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer.
Michel Toubeau (2004)
10.1097/MNM.0b013e3283622f3d
Thyroid lobe ablation with iodine-131 in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities
Luca Giovanella (2013)
Utility of the radioiodine whole-body retention at 48 hours for Page 356 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
D Van Nostrand (2009)
10.1002/cncr.26425
A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma.
Leo A Niemeier (2012)
10.1016/S1470-2045(08)70132-3
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.
Armando Bartolazzi (2008)
10.1016/j.yasu.2005.04.009
The differentiation of benign and malignant thyroid nodules.
Carrie Lubitz (2005)
Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Cinzia Pettinato (2012)
10.1111/j.1365-2559.1992.tb00963.x
Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes.
Yoshikatsu Mizukami (1992)
10.1007/s00268-010-0720-0
Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy
Willieford Moses (2010)
10.1067/msy.2001.118708
Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy.
Damian E Dupuy (2001)
10.1001/jama.292.21.2632
A 64-year-old woman with a thyroid nodule.
Susan J. Mandel (2004)
Woodson Page 313 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
M Barczynski (2013)
10.1089/thy.1998.8.737
Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
David S. Cooper (1998)
10.4158/EP.7.4.237
Role of repeated fine-needle aspiration of thyroid nodules with benign cytologic features.
Joe M. Chehade (2001)
10.1148/radiol.11110206
Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk.
Jin Young Kwak (2011)
10.1210/jc.2013-3584
An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
Bryan McIver (2014)
BRAF mutation and its association with clinicopathological features of papillary thyroid cancer: a metaanalysis
C Li (2012)
Impact of initial surgical treatment on Page 295 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Duren (2000)
10.4103/2230-8210.104031
Thyroid disorders in pregnancy
M. Ramprasad (2012)
10.1089/thy.2012.0190
Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
Pedro Weslley Rosario (2012)
Thyroid lobe ablation with iodine-131I 106 HAUGEN ET AL. in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities
L Giovanella (2013)
10.1245/s10434-012-2594-x
Effect of Prophylactic Central Compartment Neck Dissection on Serum Thyroglobulin and Recommendations for Adjuvant Radioactive Iodine in Patients with Differentiated Thyroid Cancer
Tracy S. Wang (2012)
10.1089/thy.2008.0271
Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy?
Utaroh Motosugi (2009)
10.1111/j.1365-2265.2006.02605.x
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Tae Yong Kim (2006)
10.1097/01.sla.0000186421.30982.d2
Follicular Thyroid Carcinoma: The Role of Histology and Staging Systems in Predicting Survival
Chung Yau Lo (2005)
10.1002/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO;2-1
Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy.
Jae Ho Kim (1987)
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Edna Teruko Kimura (2003)
10.1089/thy.2011.0487
Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.
Ji Hye Yim (2013)
10.1007/s12020-013-0078-9
Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer
Daniel Mankarios (2013)
10.1210/jcem.82.12.4466-8
Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.
Amiel Z. Rudavsky (1997)
10.1210/jc.2010-0162
The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients.
Guillaume Chambon (2011)
10.1097/00003072-198708000-00014
Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma.
Françesca Pons (1987)
10.1007/BF00577738
Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts
A. Antonelli (2004)
10.1210/jcem.86.4.7405
Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects.
Mira S T Torres (2001)
10.1002/dc.21477
Follicular lesions of the thyroid: a retrospective study of 1,348 fine needle aspiration biopsies.
S Wu (2012)
10.1210/jc.2003-031139
Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
Dina I. Serhal (2004)
10.1080/00313020220131291
Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma
K T Mai (2002)
10.1016/j.surg.2014.08.060
Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
Aya Ebina (2014)
10.1259/bjr/92548685
A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Alexandra Léger (2005)
10.1089/thy.2005.15.1169
Interobserver variation for ultrasound determination of thyroid nodule volumes.
Volker F. H. Brauer (2005)
10.1097/MD.0b013e31826a9c71
BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis
Ralph P Tufano (2012)
10.1089/105072502753522356
Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma.
Douglas van Nostrand (2002)
10.1530/EJE-13-0888
Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement.
Charlotte Lepoutre-lussey (2014)
10.1016/S0098-1672(10)79205-5
Partially Cystic Thyroid Nodules on Ultrasound: Probability of Malignancy and Sonographic Differentiation
Anne G Osborn (2010)
10.1210/jc.2013-3160
Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration.
Eric Nou (2014)
10.4158/EP14066.PS
AACE/ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology.
Victor J. Bernet (2014)
Molecular alterations in partiallyencapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma
BE Howitt (2013)
10.1007/s11764-014-0345-7
Unmet information and support needs in newly diagnosed thyroid cancer: comparison of adolescents/young adults (AYA) and older patients
Melanie Goldfarb (2014)
Papillary microcarcinoma of the thyroid—prog ATA THYROID NODULE/DTC GUIDELINES 97 nostic significance of lymph node metastasis and multifocality
SM Chow (2003)
Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123–1129
A D’Avanzo (2004)
Proceedings: Effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata.
Goslings Bm (1975)
10.1007/s00268-005-7789-x
Ultrasonographically and Anatomopathologically Detectable Node Metastases in the Lateral Compartment as Indicators of Worse Relapse-free Survival in Patients with Papillary Thyroid Carcinoma
Yasuhiro Ito (2005)
10.1158/0008-5472.CAN-09-0727
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho (2009)
Principles in Thyroid Surgery. In: Randolph GW (ed). Surgery of the Thyroid and Parathyroid Glands. 2 edition
GW Randolph (2013)
10.1007/s12020-014-0410-z
Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer
Kyoungjune Pak (2014)
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Butticè Salvatore (2008)
10.1097/PAS.0b013e3181dbee07
Encapsulated Well-differentiated Follicular-patterned Thyroid Carcinomas Do Not Play a Significant Role in the Fatality Rates From Thyroid Carcinoma
Simonetta Piana (2010)
10.1177/107327480000700304
Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma.
Judith C Mccaffrey (2000)
10.1038/modpathol.3880153
Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Bone Metastases
Zubair W. Baloch (2000)
10.1111/j.1365-2265.2011.04138.x
Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
Véronique Taillard (2011)
Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases.
Bruce M. Wenig (1998)
10.1089/thy.2006.16.381
Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma.
Marina Shargorodsky (2006)
10.1089/thy.2008.0407
Recurrence after treatment of micropapillary thyroid cancer.
Douglas S. Ross (2009)
10.1080/110241501750070538
The rate of tumour growth does not distinguish between malignant and benign thyroid nodules.
Koichi Asanuma (2001)
10.1089/thy.2009.1599
Highlights of the American Thyroid Association Guidelines for patients with thyroid nodules or differentiated thyroid carcinoma: the 2009 revision.
Léonard Wartofsky (2009)
10.1016/j.ecl.2014.02.010
Update on differentiated thyroid cancer staging.
Denise Prado Momesso (2014)
10.7326/0003-4819-138-4-200302180-00010
Natural History of Benign Solid and Cystic Thyroid Nodules
Erik K. Alexander (2003)
10.1530/EJE-08-0641
Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH.
Nikos Emmanouilidis (2009)
10.1002/jcla.20339
Comparison of the influence of thyroglobulin antibodies on serum thyroglobulin values from two different immunoassays in post surgical differentiated thyroid carcinoma patients.
Marijana Stanojević (2009)
10.1097/MLG.0B013E318156F6C3
Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma.
Alex Kwok-cheung Leung (2008)
Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid 22:332–333
PW Rosario (2012)
Relationship between tumor burden and serum thyro globulin level in patients with papillary and follicular thyroid carcinoma
A Bachelot (2002)
ATA THYROID NODULE/DTC GUIDELINES
JC Sisson (2011)
10.1385/EP:16:4:279
Handling of thyroid follicular patterned lesions
Juan Rosai (2005)
10.1089/thy.2013.0124
Clinical and professional ethics guidelines for the practice of thyroidology.
M. Sara Rosenthal (2013)
10.1089/thy.2009.0455
The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
Wendy L Sacks (2010)
10.1158/1078-0432.CCR-11-2487
A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Xavier M Keutgen (2012)
Clinical practice. The thyroid nodule.
Laszlo Hegedüs (2004)
10.1210/jc.2013-2482
Multicenter clinical experience with the Afirma gene expression classifier.
Erik K. Alexander (2014)
10.1148/radiol.13122247
Thyroid nodules with initially nondiagnostic cytologic results: the role of core-needle biopsy.
Jin Sun Yeon (2013)
10.1097/CCO.0b013e32835a583d
Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges
Ji Eun Shin (2013)
10.1373/clinchem.2012.195594
Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of antithyroglobulin autoantibodies.
Mark M. Kushnir (2013)
10.1089/thy.2011.0214
Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation.
Pedro Weslley Rosario (2012)
10.1097/00003072-198911000-00001
Value of Post-Therapy Whole-Body I-131 Imaging in the Evaluation of Patients with Thyroid Carcinoma Having Undergone High-Dose I-131 Therapy
William G. Spies (1989)
10.1016/S0140-6736(14)60421-9
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose (2014)
10.1007/s00330-008-1192-6
CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck
Dae Young Yoon (2008)
10.1002/bjs.8985
Prophylactic central neck dissection for papillary thyroid cancer.
Marcin Barczyński (2013)
10.1002/cncr.27641
Patient decision aids for cancer treatment: are there any alternatives?
Gillian Spiegle (2013)
10.1002/cncr.22138
Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity.
Jeffrey C Liu (2006)
10.1089/thy.2010.0021
Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006.
Briseis Aschebrook-Kilfoy (2011)
10.1046/j.1365-2265.2002.01631.x
Preparation for radioactive iodine administration in differentiated thyroid cancer patients.
Yair Liel (2002)
10.1016/S0936-6555(03)00162-6
External beam radiotherapy in the management of differentiated thyroid cancer.
Daniel Ford (2003)
10.1148/radiol.2541090460
Value of US correlation of a thyroid nodule with initially benign cytologic results.
Jin Young Kwak (2010)
10.1155/2010/690108
Thyroid Fine Needle Aspiration Biopsies in Children: Study of Cytological-Histological Correlation and Immunostaining with Thyroid Peroxidase Monoclonal Antibodies
Victoria Hoperia (2010)
10.1210/jc.2003-032004
Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas.
Agnès Rouxel (2004)
10.1097/00000421-199802000-00018
Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
J D Lin (1998)
10.1016/j.ecl.2014.02.007
Persistent posttreatment fatigue in thyroid cancer survivors: a scoping review.
Anna M. Sawka (2014)
BRAF mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer
GM Howell (2013)
Treatment guidelines for patients with thyroid nodules and welldifferentiated thyroid cancer
PA Singer (1996)
Woodson Page 313 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Barczynski (2013)
10.1097/00000478-199303000-00010
Poorly Differentiated Thyroid Carcinomas with Primordial Cell Component: A Group of Aggressive Lesions Sharing Insular, Trabecular,and Solid Patterns
Mauro Papotti (1993)
10.1309/8VL9-ECXY-NVMX-2RQF
Follicular-patterned lesions of the thyroid: the bane of the pathologist.
Zubair W Baloch (2002)
10.1210/jcem.82.11.4386
Prognosis and treatment of brain metastases in thyroid carcinoma.
A C Chiu (1997)
10.1089/thy.2009.1602
Guidelines for guidelines: content, accountability, peer review, and intellectual ownership.
Charles H. Emerson (2009)
10.1089/105072504773297885
False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma.
Michael W. Yeh (2004)
10.1007/s00259-010-1669-9
Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up
Johannes Biko (2010)
10.1007/s00268-010-0924-3
Prognosis of Patients with Papillary Thyroid Carcinoma Showing Postoperative Recurrence to the Central Neck
Yasuhiro Ito (2010)
Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
John Muratet (1997)
10.1056/NEJMoa1108586
Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Martin Jean Schlumberger (2012)
10.1089/thy.2011.0122
Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Ozlem Soyluk (2011)
10.1007/s10434-004-1165-1
Extent of Thyroidectomy Is Not a Major Determinant of Survival in Low- or High-Risk Papillary Thyroid Cancer
MSc Frcsc Facs Philip I. Haigh MD (2004)
10.1002/cncr.26085
The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature.
Dennis Vriens (2011)
10.1210/jc.2007-0225
A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.
Tania Pilli (2007)
10.1055/s-0030-1269881
Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
Gonzalo Díaz-Soto (2011)
10.1089/thy.2010.0353
Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma.
Kiminori Sugino (2011)
10.1002/hed.22985
Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TI-RADS).
Shih-Ping Cheng (2013)
10.1210/jc.2007-0641
Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules.
Teresa Rago (2007)
10.1089/thy.2010.0248
Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma.
Gerald M Y Quan (2012)
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radioiodine refractory differentiated thyroid carcinoma : final results of a phase II trial
Tatiana C. Schneider (2012)
10.1309/AJCPXM9WIRQ8JZBJ
The Bethesda System for reporting thyroid fine-needle aspiration specimens.
Stefano Crippa (2010)
10.1210/jc.2003-030305
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
Hiroyuki Namba (2003)
Second primary Page 363 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
S Subramanian (2007)
Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123–1129
A D’Avanzo (2004)
10.1002/lary.21091
The surgical management of goiter: Part II. Surgical treatment and results.
Gregory W. Randolph (2011)
10.1210/jcem.81.5.8626823
Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
Matthew David Ringel (1996)
10.1089/thy.2007.0171
Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.
Shoba L. Subramanian (2007)
10.1002/(SICI)1098-2388(199901/02)16:1<12::AID-SSU3>3.0.CO;2-M
Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma.
Steven I Sherman (1999)
10.1111/j.1445-5994.2006.01149.x
Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy.
W. F. Eddie Lau (2006)
10.1677/ERC-10-0233
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
Désirée Déandréis (2011)
10.1001/archotol.130.7.819
Management and outcome of recurrent well-differentiated thyroid carcinoma.
Carsten E. Palme (2004)
10.1677/erc.1.00830
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Markus Luster (2005)
10.1210/jcem.84.11.6094
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
B Haugen (1999)
10.3174/ajnr.A2686
Role of Sonographic Diagnosis in Managing Bethesda Class III Nodules
Dongchun Kim (2011)
10.3275/7768
Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer
Ari Polachek (2011)
10.1002/jso.23345
Patients' experiences following local-regional recurrence of thyroid cancer: a qualitative study.
Shikha Misra (2013)
10.3413/nukmed-0225
The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
Frederik Anton Verburg (2009)
10.1089/thy.2010.0403
Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
James C. Sisson (2011)
10.1089/105072502753451959
Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin.
B Haugen (2002)
10.1210/jc.2002-020210
Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.
Richard T. Kloos (2002)
10.1038/modpathol.3880023
Metastatic Minimally Invasive (Encapsulated) Follicular and Hurthle Cell Thyroid Carcinoma: A Study of 34 Patients
Neal S. Goldstein (2000)
10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].
Scott A. Hundahl (1998)
10.1089/thy.2011.0198
Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.
Giuseppe Barbesino (2012)
10.1089/thy.2011.0232
In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.
Fernanda Vaisman (2011)
10.4158/EP.6.6.469
Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy.
Ernest L. Mazzaferri (2000)
10.1245/s10434-007-9531-4
Histological Aggressiveness of Fluorodeoxyglucose Positron-Emission Tomogram (FDG-PET)-Detected Incidental Thyroid Carcinomas
Chandrakanth Are (2007)
10.1016/S0194-5998(00)70047-7
Tall Cell Variant: An Aggressive Form of Papillary Thyroid Carcinoma
Steve Prendiville (2000)
10.1530/EJE-12-0400
MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
Patrizia Agretti (2012)
10.1089/thy.2011.0322
Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment.
Ji Min Han (2012)
10.1007/s00259-011-1773-5
Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer
Lutz Stefan Freudenberg (2011)
10.1089/thy.2009.0429
Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice.
Douglas van Nostrand (2010)
10.1210/jcem.82.5.4062
Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes.
Franco Arturi (1997)
Impact of 131I-SPECT/CT images obtained with an integrated system Page 348 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
K Tharp (2004)
10.1046/j.1365-2265.2000.01014.x
Ablation of the thyroid remnant and 131 I dose in differentiated thyroid cancer.
Suhail A. R. Doi (2000)
10.1210/jcem-71-2-414
Natural history, treatment, and course of papillary thyroid carcinoma.
Leslie J. Degroot (1990)
10.1001/archinte.1990.00390190082012
Cystic thyroid nodules. The dilemma of malignant lesions.
E T de los Santos (1990)
10.2214/AJR.10.5345
Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation.
Jung Hwan Baek (2011)
10.1210/jcem.87.5.8504
Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.
Enrico Papini (2002)
10.1210/jc.2005-1534
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
Richard J Robbins (2006)
10.1002/lary.21143
Long-term outcomes of injection laryngoplasty in patients with potentially recoverable vocal fold paralysis.
Lindsey Clemson Arviso (2010)
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.
Richard J Robbins (2005)
10.1089/thy.1998.8.989
Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules.
Philippe Hagag (1998)
10.1007/s00268-013-2261-9
Thyroid Nodules (≥4 cm): Can Ultrasound and Cytology Reliably Exclude Cancer?
Laura I. Wharry (2013)
10.1097/00000478-200112000-00002
Solid Variant of Papillary Thyroid Carcinoma: Incidence, Clinical–Pathologic Characteristics, Molecular Analysis, and Biologic Behavior
Yuri E Nikiforov (2001)
10.1245/s10434-013-2990-x
Thyroid Nodules with Bethesda System III Cytology: Can Ultrasonography Guide the Next Step?
Hye Mi Gweon (2013)
10.1089/thy.2005.15.274
Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up.
Augusto Orlandi (2005)
10.1016/j.surg.2011.09.003
A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer.
Aleksandra Popadich (2011)
10.1677/ERC-08-0080
Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Marco Capezzone (2008)
10.1210/jc.2011-1270
Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
Ji Hye Yim (2011)
10.1001/archotol.130.7.857
Patterns of lateral neck metastasis in papillary thyroid carcinoma.
Michael Elliot Kupferman (2004)
Lowrisk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature
L Lamartina (2015)
Relationship between tumor burden and serum thyro globulin level in patients with papillary and follicular thyroid carcinoma
A Bachelot (2002)
Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management.
Holger Palmedo (2006)
10.1089/thy.2009.0332
Oncofetal fibronectin mRNA is highly abundant in the blood of patients with papillary thyroid carcinoma and correlates with high-serum thyroid-stimulating hormone levels.
Michael Wehmeier (2010)
10.1089/thy.2013.0061
Brain metastases from thyroid carcinoma: a retrospective study of 21 patients.
Bénédicte Henriques de Figueiredo (2014)
10.1001/archsurg.141.5.489
Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.
John M. Stulak (2006)
10.1097/MLG.0b013e318162cae9
Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer.
Kathryn G. Schuff (2008)
Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TIRADS). Head Neck 35:541–547
SP Cheng (2013)
Exploring the relationship between severity of dysphonia and voicerelated quality of life
SM Jones (2006)
10.1016/j.surg.2008.08.033
Pediatric endocrine surgery: who is operating on our children?
Charles T. Tuggle (2008)
10.1002/cncr.20087
Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients.
Marco Volante (2004)
10.1259/0007-1285-50-599-799
Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.
Caroline J. Edmonds (1977)
Skeletalrelated events due to bone metastases from differentiated thyroid cancer
A Farooki (2012)
10.1530/EJE-07-0088
Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer.
Nuno Cunha (2007)
10.1046/j.1365-2265.2002.01500.x
Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours.
B Haugen (2002)
10.1111/j.1365-2303.2010.00777.x
Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18,000 FNAs reported at the same institution during 1998-2007.
Simonetta Piana (2011)
Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.
K B Johansen (1991)
10.1097/00000658-199605000-00003
Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up.
Jennifer Olson (1996)
10.1002/dc.20830
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference.
Zubair W Baloch (2008)
10.3346/jkms.2014.29.6.811
The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
Kyoungjune Pak (2014)
10.1002/jso.10089
Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
Jen-Der Lin (2002)
BRAF status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma
JD Prescott (2012)
Management of invasive well-differentiated thyroid cancer an American Head and Neck Society consensus statement. Head Neck 36:1379–1390
ML Shindo (2014)
Clinical experience with recombinant human Page 358 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
G Mariani (2000)
10.1080/0031302031000150533
Thyroid pathology in four patients with Cowden's disease.
Christine T Hemmings (2003)
Clinical experience with recombinant human Page 358 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
G Mariani (2000)
10.1093/ajcp/85.1.77
Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma.
Harry L. Evans (1986)
10.1007/s00259-005-1866-0
Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer
Marie-Odile Bernier (2005)
10.1111/j.1365-2559.1994.tb01374.x
Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm.
H. Rubén Harach (1994)
Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer.
Salil D. Sarkar (1976)
10.1097/SLA.0b013e31824b7b68
Optimization of Staging of the Neck With Prophylactic Central and Lateral Neck Dissection for Papillary Thyroid Carcinoma
Dana M. Hartl (2012)
Long-term outcomes of injection laryngoplasty in patients with potentially recoverable vocal fold paralysis. Laryngoscope 120:2237–2240
LC Arviso (2010)
10.1007/s00259-002-0785-6
Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I
Thomas E. Hilditch (2002)
10.1002/hed.21414
Role of core needle biopsy and ultrasonographic finding in management of indeterminate thyroid nodules.
Kyung Tae Park (2011)
10.1007/s00268-004-7604-0
Modified Radical Neck Dissection for Differentiated Thyroid Cancer: Operative Technique
Shinya Uchino (2004)
10.1089/thy.2008.0392
Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Anna M Sawka (2009)
10.1111/j.1365-2265.2010.03898.x
Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?
Joanna Kłubo-Gwieździńska (2011)
10.1046/j.1365-2265.2002.01482.x
Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma -- surgery or conventional therapy?
Georg Zettinig (2002)
10.1210/jcem-34-5-814
Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma.
Jerome M. Hershman (1972)
10.1016/S0360-3016(02)04203-7
Value of external irradiation for locally advanced papillary thyroid cancer.
Tae-Hyun Kim (2003)
10.1089/thy.2010.1641
Familial syndromes associated with thyroid cancer in the era of personalized medicine.
Melanie L. Richards (2010)
10.1530/EJE-11-0181
Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology.
Guido Fadda (2011)
Friguglietti CU 2013 BRAF: A Tool in the Decision to Perform Elective Neck Dissection? Thyroid
SE Dutenhefner (2013)
10.1309/AJCP4P2GCCDNHFMY
Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach?
Paul A VanderLaan (2011)
10.1007/s00268-007-9033-3
An evidence-based review of poorly differentiated thyroid cancer
Enoch M. Sanders Jr. (2007)
Diagnostic pathology and molecular genetics of the thyroid
Yuri E Nikiforov (2009)
10.1007/s00268-013-2345-6
Prognostic Significance of the Number of Metastatic Lymph Nodes to Stratify the Risk of Recurrence
Jeonghun J. Lee (2013)
10.1097/MNM.0b013e32834e306a
Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial
Babak Fallahi (2012)
Treatment of scannegative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone
AZ Rudavsky (1997)
10.1007/s002689900130
Improved Survival of Patients with Papillary Thyroid Cancer after Surgical Microdissection
Lars-Erik Tisell (1996)
10.4158/10024.GL
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules.
H. Gharib (2010)
10.1016/j.suronc.2009.06.006
Diagnostic and therapeutic strategies for minimally and widely invasive follicular thyroid carcinomas.
Chao-Chun Huang (2011)
10.1210/jcem.85.1.6254
Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study.
Francesco Cetta (2000)
[Radioiodine in the treatment of thyroid cancer].
Edward Eric Sir Pochin (1957)
10.1055/s-0029-1241861
Impact of pregnancy on prevalence of goitre and nodular thyroid disease in women living in a region of borderline sufficient iodine supply.
Stefan Karger (2010)
10.1016/j.surg.2011.08.016
Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy.
Iain J Nixon (2012)
10.1080/02841850902740940
Are there any specific ultrasound findings of nodular hyperplasia (“leave me alone” lesion) to differentiate it from follicular adenoma?
Won-Jin Moon (2009)
10.1007/s00268-010-0776-x
Prognostic Impact of Extrathyroid Extension and Clinical Lymph Node Metastasis in Papillary Thyroid Carcinoma Depend on Carcinoma Size
Mitsuhiro Fukushima (2010)
10.1007/s00268-011-1397-8
How to Manage Thyroid Nodules With Two Consecutive Non-Diagnostic Results on Ultrasonography-Guided Fine-Needle Aspiration
Hee Jung Moon (2011)
10.1097/01.mnm.0000126626.17166.ed
Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation
Ya-Hui Hu (2004)
10.1016/S1470-2045(12)70335-2
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux (2012)
10.1016/j.surg.2013.04.033
Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients.
Eric J. Kuo (2013)
10.1016/j.yexmp.2014.08.005
Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
Shu Fang Liu (2014)
10.1089/thy.2005.15.1321
Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis.
Jennifer P Holst (2005)
10.1016/J.SURG.2013.06.034
Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
S Kruijff (2013)
BRAF mutation and its association with clinicopathological features of papillary thyroid cancer: a metaanalysis
C Li (2012)
Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
Bernhard Schlüter (2001)
10.1245/s10434-010-1144-7
Rehospitalization among Elderly Patients with Thyroid Cancer after Thyroidectomy are Prevalent and Costly
Charles Thompson Tuggle (2010)
10.1089/105072502320908321
Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
Gregory W. Randolph (2002)
Long-term thyrotropinsuppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma
M Shargorodsky (2006)
Principles in thyroid surgery. In: Randolph GW (ed) Surgery of the Thyroid and Parathyroid Glands. 2nd edition
GW Randolph (2013)
10.1245/s10434-010-1398-0
Same-Day Thyroidectomy: A Review of Practice Patterns and Outcomes for 1,168 Procedures in New York State
Charles Thompson Tuggle (2010)
Impact of initial surgical treatment
M Duren (2000)
Are cancerrelated decision aids effective? A systematic review and meta-analysis
MA O’Brien (2009)
Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123-1129 Page 314 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y
A D'Avanzo (2004)
The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma
Richard J Robbins (2005)
10.1007/s00761-010-1871-1
Die Rolle der externen Strahlentherapie bei der Behandlung des Schilddrüsenkarzinoms
Dirk Vordermark (2010)
10.1089/thy.2009.0110
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S. Cooper (2009)
10.1016/0959-8049(93)90574-Y
Prognostic importance of various clinicopathological features in papillary thyroid carcinoma.
Lars A. Akslen (1992)
10.1097/RCT.0b013e31818fb3f1
Detection of Metastatic Cervical Lymph Nodes in Recurrent Papillary Thyroid Carcinoma: Computed Tomography Versus Positron Emission Tomography-Computed Tomography
Dong Hoon Lee (2009)
10.1002/cncy.21455
Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Ricardo R. Lastra (2014)
Lung metastases from differentiated thyroid carcinoma. A 40 years' experience.
Giuseppe Ronga (2004)
10.1089/thy.2011.0423
American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery.
Sally E. Carty (2012)
10.1200/JCO.2011.37.1195
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Fábio Augusto Barros Schutz (2012)
10.1002/hed.21020
Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma.
Steven Orlov (2009)
10.1016/S0039-6060(98)70035-2
Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?
Ian D. Hay (1998)
10.1111/j.1365-2265.2004.02060.x
Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.
Carmen F A Eustatia-Rutten (2004)
10.1210/jc.2014-3169
Cancer-related worry in Canadian thyroid cancer survivors.
Lauren Bresner (2015)
10.1210/jcem.80.7.7608252
Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades.
S F Dinneen (1995)
10.1002/1097-0142(20011101)92:9<2273::aid-cncr1573>3.0.co;2-y
Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study.
Rocco Domenico Alfonso Bellantone (2001)
10.1089/thy.2014.0572
Sialendoscopy for Patients with Radioiodine-Induced Sialadenitis and Xerostomia.
Mihir K Bhayani (2015)
10.1002/cncr.26070
Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Narayanan Gopalakrishna Iyer (2011)
10.1007/s00268-002-6670-4
Complications of Neck Dissection for Thyroid Cancer
Wei Keat Cheah (2002)
10.1016/S0140-6736(01)06971-9
15 years after Chernobyl: new evidence of thyroid cancer
Yoshisada Shibata (2001)
10.1001/archsurg.2009.116
Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger.
Scott N. Pinchot (2009)
10.1007/s00268-012-1674-1
Preoperative Ultrasonography Assessment of Vocal Cord Movement During Thyroid and Parathyroid Surgery
Shih-Ping Cheng (2012)
10.1210/jc.2012-3933
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Mona M Sabra (2013)
10.1118/1.594287
In vivo quantitation of lesion radioactivity using external counting methods.
Stephen R. Thomas (1976)
10.1210/jcem.83.3.4615
Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.
Enrico Papini (1998)
10.1097/RLU.0b013e318203bb84
Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body Scan
Luca Giovanella (2011)
10.1001/archoto.2010.212
Volume-based trends in thyroid surgery.
Christine G Gourin (2010)
10.1210/jc.2002-021365
Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Eric Baudin (2003)
10.1007/s00268-010-0469-5
Managing Patients with a Preoperative Diagnosis of AJCC/UICC Stage I (T1N0M0) Papillary Thyroid Carcinoma: East Versus West, Whose Policy is Best?
Ian D. Hay (2010)
10.1016/j.amjsurg.2009.08.030
Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.
Insoo Suh (2010)
10.6004/JNCCN.2011.0137
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
Phillip G. Febbo (2011)
10.1089/thy.2012.0005
Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review.
Kerstin Soelberg (2012)
10.1200/JCO.2014.55.5094
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing (2014)
10.1507/endocrj.k06-166
Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.
Tae Sik Jung (2007)
10.1210/jc.2006-0527
Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration.
Kristien Boelaert (2006)
10.1164/rccm.201108-1575ST
An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy.
Ann N C Leung (2011)
10.1001/jama.297.23.2633
The locality rule and the physician's dilemma: local medical practices vs the national standard of care.
Michelle Huckaby Lewis (2007)
10.1001/archinte.1996.00440180017002
Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association.
Peter A. Singer (1996)
10.1097/00000658-200202000-00015
Laryngeal Recurrent Nerve Injury in Surgery for Benign Thyroid Diseases: Effect of Nerve Dissection and Impact of Individual Surgeon in More Than 27,000 Nerves at Risk
Michael Hermann (2002)
10.2214/AJR.09.2386
Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT.
Ji Soo Choi (2009)
10.1001/archsurg.135.2.204
A prospective evaluation of recurrent laryngeal nerve paralysis during thyroidectomy.
Chung Yau Lo (2000)
10.1002/cncr.26500
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Tae Hyuk Kim (2012)
10.1210/jc.2005-1085
Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal.
Wichert J. Kuijt (2005)
10.1210/jcem.82.2.3737
Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group.
Patricia Niccoli (1997)
10.1089/thy.2008.0428
Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Annalisa Panico (2009)
10.1177/0272989X10395029
Information for Decision Making by Patients With Early-Stage Prostate Cancer
Deb Feldman-Stewart (2011)
10.1016/s0272-2712(18)30434-7
Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies.
H. Gharib (1993)
10.1016/S0022-3468(98)90546-2
The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer.
Daniel K. Robie (1998)
10.1097/01.mlg.0000154730.31281.0c
Thyroglobulin before ablation and correlation with posttreatment scanning.
Pedro Weslley Souza de Rosário (2005)
10.1038/modpathol.2011.2
Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma
Jey-Hsin Chen (2011)
Locally advanced thyroid cancer: therapeutic options.
Nicola Avenia (2004)
10.4158/EP.10.3.261
Challenges in neck ultrasonography: lymphadenopathy and parathyroid glands.
Andrea Frasoldati (2004)
10.1210/jcem.86.8.7717
The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
Lilah F. Morris (2001)
10.1210/jc.2007-2496
Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis.
Kevin Cheung (2008)
10.1089/thy.2010.0028
Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
Anastasios Gkountouvas (2010)
10.1007/s00595-012-0353-z
Long-term results of surgery for papillary thyroid carcinoma with local recurrence
Hiroki Uchida (2012)
Prognostic value of the tall cell variety of papillary cancer of the thyroid.
Alfredo Moreno Egea (1993)
10.1097/00003072-199803000-00011
Unilateral radioiodine breast uptake.
Siema M. Bakheet (1998)
10.1007/s00268-009-0353-3
The Impact of Intraoperative Neuromonitoring (IONM) on Surgical Strategy in Bilateral Thyroid Diseases: Is it Worth the Effort?
Peter E Goretzki (2009)
10.1177/030089169007600513
Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy
Jean Pierre Droz (1990)
10.2967/jnumed.110.081059
Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 Cases
Tatsuya Higashi (2011)
10.1097/00000478-200208000-00005
Thyroid Carcinomas With Distant Metastases: A Review of 111 Cases With Emphasis on the Prognostic Significance of an Insular Component
Myriam Decaussin (2002)
10.1046/j.1365-2265.2002.t01-1-01545.x
Testicular dose and fertility in men following I(131) therapy for thyroid cancer.
Stephen Hyer (2002)
10.4158/EP10134.OR
Cystic lymph nodes in the lateral neck as indicators of metastatic papillary thyroid cancer.
Christine S. Landry (2011)
Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large Page
M Shargorodsky (2006)
Change of serum antithyroglobulin antibody levels is useful for Page 329 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
WG Kim (2008)
10.1089/THY.2014.0502
American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making
Richard T. Kloos (2015)
10.1016/j.surg.2004.06.045
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma.
Maria A Kouvaraki (2004)
10.1210/jcem.84.11.6115
Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases.
Yukihiko Kitamura (1999)
10.1097/00000658-199804000-00014
Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group.
Kurt D. Newman (1998)
10.1007/s00268-012-1507-2
Level VI Lymph Node Dissection Does Not Decrease Radioiodine Uptake in Patients Undergoing Radioiodine Ablation for Differentiated Thyroid Cancer
Don C. Yoo (2012)
10.1016/S0720-048X(97)00184-8
Preoperative staging of thyroid papillary carcinoma with ultrasonography.
Kazuaki Shimamoto (1998)
10.1210/jcem.82.9.4247
Outcome of differentiated thyroid cancer diagnosed in pregnant women.
Mohammad Kasim Moosa (1997)
10.1089/thy.2010.0055
Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review.
Anna M Sawka (2010)
10.2967/jnumed.110.075960
The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer
Ravinder Kaur Grewal (2010)
10.1111/j.1365-2265.2011.04002.x
Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.
Fernanda Vaisman (2011)
10.1089/thy.2007.0061
Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications.
Ronald A. Ghossein (2007)
10.1002/jso.10189
Role of metastasectomy in the management of thyroid carcinoma: the NIH experience.
Ho David Pak (2003)
10.1089/thy.2008.0243
Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.
S Baek (2010)
10.1007/978-3-540-47648-1_4368
Papillary carcinoma.
Juan Rosai (1993)
10.1111/j.1365-2265.2005.02358.x
Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
James Brierley (2005)
10.1007/s00259-008-1044-2
Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen
Susanne Kohlfuerst (2008)
10.1097/00005537-200009000-00011
Vocal fold paralysis after anterior cervical spine surgery: incidence, mechanism, and prevention of injury.
M D Kriskovich (2000)
10.1210/jc.2005-0987
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing (2005)
10.1007/s00268-009-0303-0
An Observational Trial for Papillary Thyroid Microcarcinoma in Japanese Patients
Yasuhiro Ito (2009)
10.1097/mnm.0b013e328365ac05
rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis
Chao Ma (2013)
10.1089/thy.2013.0557
Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management.
Jason B. Clain (2014)
10.1210/jc.2012-1553
Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients.
Eyal Robenshtok (2012)
10.1007/s00464-010-1296-3
Perioperative clinical outcomes after robotic thyroidectomy for thyroid carcinoma: a multicenter study
Jandee Lee (2010)
10.1001/archotol.1997.01900090016003
Pretherapeutic staging of hypopharyngeal carcinoma. Clinical findings, computed tomography, and magnetic resonance imaging compared with histopathologic evaluation.
Peter Zbären (1997)
10.1016/S1072-7515(03)00421-6
Lymph node surgery in papillary thyroid carcinoma.
Ernst Gemsenjaeger (2003)
10.1007/BF02067365
The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy
Janice L. Pasieka (2005)
10.1111/j.1365-2362.2009.02162.x
Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination.
Sabine Guth (2009)
10.1089/thy.2006.0337
Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules.
Hyun Jung Tae (2007)
10.4158/EP.13.5.498
Management of low-risk differentiated thyroid cancer.
Ernest L. Mazzaferri (2007)
10.1002/cncy.20124
Improved preoperative definitive diagnosis of papillary thyroid carcinoma in FNAs prepared with both ThinPrep and conventional smears compared with FNAs prepared with ThinPrep alone.
Martin H. Luu (2011)
10.1001/archsurg.2009.48
Outcomes following thyroid and parathyroid surgery in pregnant women.
Sreyram Kuy (2009)
10.1136/bmj.d8041
Influence of experience on performance of individual surgeons in thyroid surgery: prospective cross sectional multicentre study
A. Margot Duclos (2012)
10.1007/s00259-004-1516-y
Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases
Levent Kabasakal (2004)
10.1089/thy.2014.0343
Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer.
James X Wu (2015)
10.1590/S0004-27302009000900014
Latin American thyroid society recommendations for the management of thyroid nodules.
Rosalinda Camargo (2009)
Changes in risk factors and Tumor Node Metastasis Page 280 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
H Karga (2011)
10.7326/0003-4819-159-5-201309030-00006
A Prospective Assessment Defining the Limitations of Thyroid Nodule Pathologic Evaluation
Edmund S Cibas (2013)
10.1016/S0140-6736(13)60109-9
Progress in molecular-based management of differentiated thyroid cancer
Michael Xing (2013)
10.1210/jc.2005-2838
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
Cosimo Durante (2006)
Reoperative thyroid surgery.
Kenneth E. Levin (1992)
10.1097/00003072-200412000-00005
Post I-131 Therapy Scanning in Patients With Thyroid Carcinoma Metastases: An Unnecessary Cost or a Relevant Contribution?
Pedro Wesley Souza Do Rosário (2004)
10.1089/thy.2008.0332
The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes.
Chan-Kwon Jung (2009)
10.1111/j.1365-2265.2011.04272.x
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma.
Stefanie Diessl (2012)
10.1016/0014-2964(79)90291-3
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.
David P. Byar (1979)
10.4158/EP10123.OR
Autoimmune thyroid disease: a risk factor for thyroid cancer.
Ghobad Azizi (2011)
10.1007/978-0-387-87666-5_5
Follicular Neoplasm/Suspicious for a Follicular Neoplasm
Michael R. Henry (2010)
10.1210/jc.2003-030838
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Marina N Nikiforova (2003)
10.1210/jc.2007-2696
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility.
Marina N Nikiforova (2008)
10.3275/7571
The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma
Maria Grazia Castagna (2011)
10.1210/jc.2003-031573
Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma.
Richard J Robbins (2004)
Measurement of serum TSH and thyroid hormones in the ATA THYROID NODULE/DTC GUIDELINES 117 management of treatment of thyroid carcinoma with radioiodine
CJ Edmonds (1977)
The role of total thyroidectomy in the management of differentiated thyroid cancer.
Stephenson Bm (1994)
10.1097/00003072-198303000-00006
Low Iodine Diet in I-131 Ablation of Thyroid Remnants
Harry R. Maxon (1983)
10.1210/jcem-36-6-1143
The Effect of 131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma
Robert D. Leeper (1973)
Thyroid carcinoma. Lancet 361:501–511
SI Sherman (2003)
Application of postsurgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma
A Vaisman (2010)
Clinical experience with recombinant human Page 358 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
G Mariani (2000)
Are cancerrelated decision aids effective? A systematic review and meta-analysis
MA O’Brien (2009)
An evidencebased review of poorly differentiated thyroid cancer
EM Sanders (2007)
10.1002/lary.21084
The surgical management of goiter: Part I. Preoperative evaluation.
Jennifer J Shin (2011)
10.1016/S1470-2045(10)70203-5
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Keith C Bible (2010)
10.1002/cncr.11031
Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
Andrea Frasoldati (2003)
10.1089/thy.2012.0043
The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.
Gregory W. Randolph (2012)
10.1002/1097-0339(200012)23:6<425::AID-DC14>3.0.CO;2-3
Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations.
Zubair W Baloch (2000)
10.1148/radiol.11110839
Diagnostic performance of gray-scale US and elastography in solid thyroid nodules.
Hee Jung Moon (2012)
10.1089/thy.2009.0430
(124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer.
Douglas van Nostrand (2010)
Evaluation and treatment of aerodigestive tract invasion by welldifferentiated thyroid carcinoma
JC McCaffrey (2000)
10.1016/j.surg.2006.07.017
The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: a comparative study on 1000 nerves at risk.
Wai-fan Chan (2006)
10.1210/jc.2003-031000
Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial.
Finn Noe Bennedbaek (2003)
10.1200/JCO.2008.20.2382
Simplifying the TNM system for clinical use in differentiated thyroid cancer.
Adedayo A. Onitilo (2009)
10.1210/jc.2006-0993
Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.
Robert Christian Smallridge (2007)
10.7863/jum.2007.26.10.1359
Sonographic findings in the surgical bed after thyroidectomy: comparison of recurrent tumors and nonrecurrent lesions.
Jung Hee Shin (2007)
10.1007/BF03347421
Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation
Dimitrios Thomas (2007)
10.1016/j.surg.2004.07.018
Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery.
Henning Dralle (2004)
10.1089/thy.2006.16.109
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S. Cooper (2006)
10.1089/thy.2006.16.555
Comparison of palpation-guided fine-needle aspiration biopsy to ultrasound-guided fine-needle aspiration biopsy in the evaluation of thyroid nodules.
Mustafa Onur Cesur (2006)
10.1002/dc.21754
The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy.
Howard H Wu (2012)
10.1200/JCO.2012.42.4457
Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer.
Limin Yang (2013)
10.1016/j.surg.2011.09.013
Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Iwao Sugitani (2011)
10.1089/thy.2004.14.1091
Papillary thyroid carcinomas with lung metastases.
Jen-Der Lin (2004)
10.1210/jc.2009-1624
Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients.
Hernan P Tala Jury (2010)
10.1160/nukmed-0288
[Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer].
Christiane Franzius (2007)
10.1677/ERC-07-0229
Bone metastases from differentiated thyroid carcinoma.
Marius Muresan (2008)
10.1016/j.surg.2005.08.031
Preoperative evaluation of thyroid nodules with 18FDG-PET/CT.
Jamie C. Mitchell (2005)
10.1530/EJE-13-0903
Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features.
Ilaria Messuti (2014)
10.1007/s00268-004-7644-5
Papillary Microcarcinoma of the Thyroid: How Should It Be Treated?
Yasuhiro Ito (2004)
10.1007/s002590050535
Testicular function after radioiodine therapy for thyroid carcinoma
Maria Wichers (2000)
10.1002/hed.21520
Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer.
Juliana Pereira Almeida (2011)
10.1677/erc.1.01320
Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.
Sin-Ming Chow (2006)
Assessment of molecular testing in 98 HAUGEN ET AL. fine-needle aspiration biopsy samples: an experience in a Chinese population
S Liu (2014)
10.1097/MNM.0b013e3280964eae
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET–CT
Trond Velde Bogsrud (2007)
10.1007/s00464-010-1113-z
Differences in postoperative outcomes, function, and cosmesis: open versus robotic thyroidectomy
Jandee Lee (2010)
10.4158/EP.4.5.282
Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin.
M L Adler (1998)
Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma.
Maurizio Marchesi (2003)
10.1007/s00268-005-0270-z
Prognostic Significance of Extrathyroid Extension of Papillary Thyroid Carcinoma: Massive but Not Minimal Extension Affects the Relapse-free Survival
Yasuhiro Ito (2005)
10.1007/978-0-387-24472-3_12
Medullary thyroid carcinoma.
Douglas B. Evans (1997)
10.1097/00003081-199703000-00009
Thyroid nodular disease in pregnancy: current diagnosis and management.
Irving B. Rosen (1997)
10.1089/thy.2008.0419
The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
Douglas van Nostrand (2009)
10.1089/thy.2009.0386
Thyroid cancer in childhood: a retrospective review of childhood course.
Clodagh S M O'Gorman (2010)
10.1002/cncr.29038
Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
Yuri E Nikiforov (2014)
10.1089/thy.2011.0442
Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy.
Carrie Lubitz (2012)
10.1210/jc.2011-1663
Management of recurrent/persistent papillary thyroid carcinoma: efficacy of the surgical option.
Kathryn G. Schuff (2011)
10.1158/1078-0432.CCR-14-2915
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
Stephen M. Rothenberg (2014)
10.1210/jc.2013-1059
Twenty-five years after Chernobyl: outcome of radioiodine treatment in children and adolescents with very high-risk radiation-induced differentiated thyroid carcinoma.
Christoph Reiners (2013)
10.1002/hed.23615
Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative.
Mark L. Urken (2015)
10.1016/j.clon.2010.05.005
Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Miao Chao (2010)
10.1210/jc.2008-0962
Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma.
Won Gu Kim (2008)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian (2012)
Update on differentiated thyroid cancer
DP Momesso (2014)
Preoperative FDG-PET imaging to assess the ma 100 HAUGEN ET AL. lignant potential of follicular neoplasms of the thyroid
RB Smith (2008)
10.1089/thy.2009.1601
The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus- to evidence-based practice.
Efisio Puxeddu (2009)
10.1210/jc.2001-011151
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer.
Ferruccio Santini (2002)
10.1245/s10434-008-0044-6
Central Cervical Nodal Metastasis from Papillary Thyroid Microcarcinoma: Pattern and Factors Predictive of Nodal Metastasis
Jong-Lyel Roh (2008)
Assessment of molecular testing in 98 HAUGEN ET AL. fine-needle aspiration biopsy samples: an experience in a Chinese population
S Liu (2014)
Papillary microcarcinoma of the thyroid—prog ATA THYROID NODULE/DTC GUIDELINES 97 nostic significance of lymph node metastasis and multifocality
SM Chow (2003)
Serum thyroglobulin in the followup of patients with treated differentiated thyroid cancer
M Ozata (1994)
The role of [18F]-2fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature
D Vriens (2011)
10.1016/j.surg.2008.08.034
The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma.
Victor M. Zaydfudim (2008)
10.1016/j.otohns.2007.09.008
Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid
Russell B. Smith (2008)
10.1007/s00259-009-1299-2
Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation
Daniela Schmidt (2009)
10.3275/7048
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations.
H. Gharib (2010)
10.1016/j.ejso.2006.12.016
99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
Domenico Rubello (2007)
10.1016/j.surg.2005.08.009
The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy.
Gregory W. Randolph (2006)
10.1089/thy.2009.0451
Is screening appropriate for occult cervical lymph node metastases in patients with well-differentiated thyroid cancer?
Keith S. Heller (2010)
10.1210/jcem.82.11.4373
Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Kenneth C Loh (1997)
10.1530/EJE-11-0156
Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer.
Renaud Ciappuccini (2011)
10.1089/105072503321582060
Radioactive iodine and the salivary glands.
Susan J. Mandel (2003)
10.1210/jc.2012-2909
The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.
Aubrey A Carhill (2013)
10.1002/hed.23277
Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients.
David César Lesnik (2014)
10.1158/1078-0432.CCR-08-0933
High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma
Ying C. Henderson (2009)
10.1016/S0025-6196(12)62641-X
Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome.
William M. McConahey (1986)
10.1046/j.1365-2265.2002.01611.x
Gonadal damage from 131I therapy for thyroid cancer.
Ernest L. Mazzaferri (2002)
10.1007/BF03343973
Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer
N. Lima (2002)
Pathology and genetics of tumours of endocrine organs
Ronald A DeLellis (2004)
10.2967/jnumed.107.040311
Comparison of Outcomes After 123I Versus 131I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma
Edward B. Silberstein (2007)
10.1089/thy.1998.8.377
Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration.
Robert Michael Tuttle (1998)
10.1245/ASO.2006.03.062
Diffuse Sclerosing Variant of Papillary Carcinoma of the Thyroid: A 35-Year Comparative Study at a Single Institution
MD PhD Frcpa Alfred King Yin Lam MBBS (2006)
10.3109/0284186X.2012.742959
High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis
Antonis Valachis (2013)
10.1007/s12149-012-0637-9
Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131)
Marin Prpić (2012)
10.1016/0002-9343(87)90758-3
Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients.
W J Simpson (1987)
10.1210/jcem-53-6-1199
Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer.
Arthur B. Schneider (1981)
10.1089/thy.2014.0502
American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.
Robert L Ferris (2015)
Incidence of metastatic welldifferentiated thyroid cancer in cervical lymph nodes
TS Wang (2004)
Change of serum antithyroglobulin antibody levels is useful for Page 329 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
WG Kim (2008)
10.1016/j.ijrobp.2008.05.012
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience.
Stephanie A Terezakis (2009)
10.1148/radiol.10092440
Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation.
Désirée Déandréis (2011)
10.1097/PCR.0000000000000086
Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance
Su'e Chang (2015)
10.1089/thy.2010.1617
Resveratrol, thyroid cancer, and iodide: drink up?
John C Morris (2010)
10.1002/jcu.1870200107
Clinical versus ultrasound examination of the thyroid gland in common clinical practice.
Antti Brander (1992)
10.3174/ajnr.A2204
Sonographic Differentiation of Partially Cystic Thyroid Nodules: A Prospective Study
Dong Wook Kim (2010)
10.1245/s10434-010-1470-9
Central Compartment Reoperation for Recurrent/Persistent Differentiated Thyroid Cancer: Patterns of Recurrence, Morbidity, and Prediction of Postoperative Hypocalcemia
Jong-Lyel Roh (2010)
10.1097/00000478-199608000-00005
Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid.
Mary L. Ostrowski (1996)
10.1200/JCO.2010.30.1655
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.
Martin Kocher (2011)
Prevalence and causes of dysphonia in a large treatmentseeking population
SM Cohen (2012)
10.1089/thy.2006.16.1229
Outcomes of patients with differentiated thyroid carcinoma following initial therapy.
Jacqueline Jonklaas (2006)
10.1007/BF03348277
Serum thyroglobulin in thyroid carcinoma and other thyroid disorders
Furio Pacini (1980)
10.1038/modpathol.2008.105
MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma
Y Chen (2008)
10.1007/BF03347243
Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer
Ali S Alzahrani (2005)
10.1210/jc.2011-0520
I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer.
Frederik Anton Verburg (2011)
10.1517/13543784.2011.614230
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
Pamela jo Harris (2011)
Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Chao Ma (2005)
10.1186/1916-0216-42-38
Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? a meta-analysis of the literature
Ningjian Wang (2013)
10.4158/EP11045.CR
Life-threatening hyponatremia following a low-iodine diet: a case report and review of all reported cases.
Omar Mansour Al Nozha (2011)
10.1007/s00268-010-0714-y
Radio-Guided Excision of Metastatic Lymph Nodes in Thyroid Carcinoma: A Safe Technique for Previously Operated Neck Compartments
Yeşim Erbil (2010)
10.1089/thy.2009.0401
Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Robert Michael Tuttle (2010)
10.1097/00003072-200201000-00001
I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 Hours
Stephen K. Gerard (2002)
10.1002/bjs.5635
Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer.
Catharina Ihre Lundgren (2007)
10.1002/jcp.22187
Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications.
Angelo Carpi (2010)
10.1159/000023426
Solitary Thyroid Nodules in 93 Children and Adolescents
Wellington Hung (1999)
10.1002/1097-0142(19890215)63:4<718::AID-CNCR2820630420>3.0.CO;2-N
Sources of diagnostic error in fine needle aspiration of the thyroid.
Teresa L. Hall (1989)
10.2967/jnumed.112.105148
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0*
Edward B. Silberstein (2012)
10.1210/jc.2013-2928
The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis.
Juán Pablo Venables Brito (2014)
10.1056/NEJMoa1203208
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
Erik K. Alexander (2012)
10.1016/J.YOTO.2010.12.004
No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer
Markus Gapany (2011)
10.1016/j.humpath.2009.08.011
Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.
Michael Rivera (2010)
10.1210/jc.2005-1651
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
Furio Pacini (2006)
10.1089/thy.2013.0465
Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases.
Mona M Sabra (2014)
10.1007/s12032-011-0070-2
GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma
Jean-Philippe Spano (2011)
10.1016/S2213-8587(13)70215-8
Definition and management of radioactive iodine-refractory differentiated thyroid cancer.
Martin Jean Schlumberger (2014)
Management of invasive well-differentiated thyroid cancer an American Head and Neck Society consensus statement. Head Neck 36:1379–1390
ML Shindo (2014)
10.1089/thy.2012.0352
A low postoperative nonstimulated serum thyroglobulin level does not exclude the presence of radioactive iodine avid metastatic foci in intermediate-risk differentiated thyroid cancer patients.
Eyal Robenshtok (2013)
10.1530/EJE-11-0129
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Merina Ahmed (2011)
10.1016/j.surg.2012.08.053
Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma.
Marco Raffaelli (2012)
10.1016/S1092-9134(99)80011-2
Thyroid pathologic findings in patients with Cowden disease.
H. Rubén Harach (1999)
10.1016/j.mce.2009.10.012
Prognostic utility of BRAF mutation in papillary thyroid cancer
Mingzhao Xing (2010)
10.1097/SLA.0000000000000925
Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival: An Analysis of 61,775 Patients
Mohamed Abdelgadir Adam (2014)
10.1089/thy.2012.0606
Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement.
Frederik Anton Verburg (2013)
10.1210/jc.2014-1405
No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Beng Khiong Yap (2014)
10.1089/thy.2011.0021
Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study.
Adebowale J Adeniran (2011)
10.1210/jc.2012-3630
Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?
Anca M. Avram (2013)
10.1016/j.surg.2013.07.007
Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy.
Ian D. Hay (2013)
10.1046/j.1365-2265.2002.01574.x
Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?
Jeroen Schaap (2002)
10.1089/thy.2011.0242
Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine.
Pedro Weslley Rosario (2012)
10.7326/0003-4819-69-3-537
The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy.
J B Vander (1968)
10.1148/radiol.2211001624
Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients.
Luigi Alessandro Solbiati (2001)
10.1001/2013.jamaoto.393
Predictors of level II and Vb neck disease in metastatic papillary thyroid cancer.
Mazin Merdad (2012)
10.1007/s00423-011-0774-y
German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease
Thomas J. Musholt (2011)
10.1089/thy.2013.0362
Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Ji Min Han (2014)
10.1002/dc.10361
Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules.
Zubair W Baloch (2003)
10.1002/lary.20994
What is the appropriate extent of lateral neck dissection in the treatment of metastatic well-differentiated thyroid carcinoma?
Christian P. Hasney (2010)
Papillary microcarcinoma of the thyroid—progATA THYROID NODULE/DTC GUIDELINES 97 nostic significance of lymph node metastasis and multifocality
SM Chow (2003)
10.1016/j.crad.2004.01.015
Radiofrequency ablation of bony metastatic disease.
Anthony F Posteraro (2004)
Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
B. O. Helal (2001)
10.1210/jc.2003-030465
Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects.
Keon Wook Kang (2003)
10.1210/jcem.86.10.7950
Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches.
Andrea Corrias (2001)
10.1089/thy.2006.16.181
On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds.
N. David Charkes (2006)
10.1210/jcem.86.8.7777
Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.
Lotty Hooft (2001)
10.1002/jso.23656
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer.
Paul B Romesser (2014)
10.1210/jcem.86.4.7407
Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.
Ernest L. Mazzaferri (2001)
10.1002/cncr.22955
Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations.
Jack Yang (2007)
Surgical treatment of advanced thyroid carcinoma with aerodigestive invasion
JH Ge (2004)
10.1210/jc.2008-1724
An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management.
Eleonora Horvath (2009)
10.1089/thy.1999.9.591
Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits.
M E Toubert (1999)
10.2217/IJE.14.24
Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions
Keith C Bible (2014)
10.1038/modpathol.2010.112
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns
Michael Rivera (2010)
10.1210/jcem.86.9.7831
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
Furio Pacini (2001)
10.1016/S0002-9610(97)00274-2
Evaluation of ultrasound-guided fine-needle aspiration biopsy for thyroid nodules.
Tsuyoshi Hatada (1998)
10.1148/radiol.2533090471
Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma.
Jin Young Kwak (2009)
10.2214/ajr.177.4.1770929
Tracheal invasion by thyroid carcinoma: prediction using MR imaging.
Jiyun Wang (2001)
10.1089/thy.2009.0352
Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival.
Luc G. T. Morris (2010)
10.1089/thy.2013.0640
Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Sylvie Beaudenon-Huibregtse (2014)
10.1007/s00259-003-1448-y
Risk of second primary cancer following differentiated thyroid cancer
Emmanuelle Berthe (2003)
Fluorine-18fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133:294–299
E Kresnik (2003)
10.1001/archinte.1996.00440190059007
Management of thyroid nodules in pregnancy.
G. H. Tan (1996)
10.1002/(SICI)1097-0142(20000415)88:8<1902::AID-CNCR20>3.0.CO;2-Y
Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma.
Lars A. Akslen (2000)
10.1159/000326594
Beyond the Suspicious Thyroid Fine Needle Aspirate
Dorry L Segev (2003)
10.4065/72.10.913
Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm".
Richard T. Schlinkert (1997)
10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience.
Eric Baudin (1998)
10.1210/JC.2012-1123
Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
Cosimo Durante (2012)
10.1097/RLU.0b013e318266d4d8
Focus on High-Risk DTC Patients: High Postoperative Serum Thyroglobulin Level Is a Strong Predictor of Disease Persistence and Is Associated to Progression-Free Survival and Overall Survival
Arnoldo Piccardo (2013)
10.1210/jc.2002-020365
Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group.
J L Wémeau (2002)
10.1210/jc.2011-2512
Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
Claire Schvartz (2012)
10.1210/jc.2002-021702
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
Ernest L. Mazzaferri (2003)
10.1111/cen.12460
Clinical applications of SPECT/CT after first I-131 ablation in patients with differentiated thyroid cancer.
Shin Young Jeong (2014)
10.1016/j.amjoto.2007.04.006
Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules?
Nathan W. Hales (2008)
Fluorine-18fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133:294–299
E Kresnik (2003)
10.1210/jc.2015-1158
Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
Emmanuel Labourier (2015)
10.1097/MNM.0b013e328341c802
Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma
Michael Tamilia (2011)
10.1210/jcem.85.10.6903
Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Markus Luster (2000)
10.1016/S0140-6736(12)60868-X
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild (2012)
10.1002/jso.20656
Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.
Yale D. Podnos (2007)
10.1210/jcem.84.11.6161
Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.
Germán Eduardo Vargas (1999)
The role of total thyroidectomy in the management of differentiated thyroid cancer.
Brian M. Stephenson (1994)
10.1089/thy.2013.0291
American Thyroid Association statement on optimal surgical management of goiter.
Amy Y. Chen (2014)
10.1007/s00268-013-2224-1
Thyroid Lobectomy for Papillary Thyroid Cancer: Long-term Follow-up Study of 1,088 Cases
Kenichi Matsuzu (2013)
10.1002/hed.25023
AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons.
Brendan C Stack (2018)
10.1007/s00268-010-0398-3
Exclusion of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology After Negative 18F-Fluorodeoxyglucose Positron Emission Tomography: Interim Analysis
Amber L. Traugott (2010)
10.1590/S0004-27302010000100009
Ultrasonographic characteristics as a criterion for repeat cytology in benign thyroid nodules.
Pedro Weslley Rosario (2010)
10.1111/j.1365-2265.2011.04278.x
Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
Martin H. Cherk (2012)
10.1373/clinchem.2008.109652
Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry.
Andrew N Hoofnagle (2008)
10.1002/lary.24784
Impact of thyroid nodule size on prevalence and post-test probability of malignancy: a systematic review.
Jennifer J Shin (2015)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R. Brahmer (2012)
10.1111/j.1365-2265.2009.03693.x
Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT.
Ji Hyoung Seo (2010)
10.1097/PAI.0b013e31818935a9
Molecular Markers in Thyroid Fine-needle Aspiration Biopsy: A Prospective Study
Carmen Franco (2009)
10.1177/0194599813489662
Neural Monitored Revision Thyroid Cancer Surgery
Eimear Phelan (2013)
10.1089/thy.2013.0157
High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Peter Bartenstein (2014)
10.1089/105072501753271707
Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer.
Gabriella Pellegriti (2001)
10.1530/eje.1.01940
Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy.
Rainer Görges (2005)
10.1677/erc.1.01284
Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre.
Brian H H Lang (2007)
10.1089/thy.2014.0096
American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.
Michael Yeh (2015)
10.4158/EP10382.OR
Correlation of findings from iodine 123 scan and ultrasonography in the recommendation for thyroid fine-needle aspiration biopsy.
Jill Langer (2011)
10.1089/thy.2009.0311
Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Bernadette Biondi (2010)
10.1089/thy.2007.0029
Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification.
Melania Pulcrano (2007)
10.1111/1471-0528.13352
Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey.
Nathalie Bernard (2015)
10.1210/jc.2007-2357
Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer.
Richard T. Kloos (2008)
10.1038/ncpendmet0449
Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients
Martin Jean Schlumberger (2007)
10.1038/ncpendmet0402
The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers
Sophie Leboulleux (2007)
Thyroid Cancer Staging
Ja Young Kim (2011)
10.1007/s00268-002-6612-1
Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients
Ian D. Hay (2002)
10.1089/thy.2011.0235
Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Joanna Kłubo-Gwieździńska (2012)
10.1677/erc.1.0978
BRAF mutation in thyroid cancer.
Mingzhao Xing (2005)
10.1210/jc.2012-2991
Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer.
Enrico Papini (2013)
10.1210/jc.2011-1469
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
Yuri E Nikiforov (2011)
10.1210/jc.2014-3882
Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.
Livia Lamartina (2015)
10.1111/cen.12348
The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance.
Won Sang Yoo (2014)
10.1200/JCO.2014.59.8391
Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer.
Mohamed Abdelgadir Adam (2015)
10.1089/thy.2007.0159
Value of repeated fine needle aspirations of the thyroid: an analysis of over ten thousand FNAs.
Yolanda C. Oertel (2007)
10.1210/jc.2012-3291
Thyroglobulin in washout fluid from lymph node fine-needle aspiration biopsy in papillary thyroid cancer: large-scale validation of the cutoff value to determine malignancy and evaluation of discrepant results.
Jae Hoon Moon (2013)
10.1002/dc.20832
Post-thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference.
Lester J Layfield (2008)
10.1210/jcem.83.8.5014
Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma.
J P Travagli (1998)
10.1001/archotol.1997.01900050030003
The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma.
Judith M. Czaja (1997)
10.1007/s00268-007-9171-7
Extent of Routine Central Lymph Node Dissection With Small Papillary Thyroid Carcinoma
Yong Sang Lee (2007)
Vertebroplasty and kyphoplasty: new equipment for malignant vertebral fractures treatment.
Salvatore Masala (2003)
10.1002/jcu.20714
Cystic change in thyroid carcinoma: Prevalence and estimated volume in 360 carcinomas.
Tara L Henrichsen (2010)
10.1210/jcem-50-4-734
Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer.
Jerome M. Goldman (1980)
10.3949/ccjm.43.4.207
The many appearances of papillary carcinoma of the thyroid.
Hawk Wa (1976)
10.1016/S0037-198X(02)80035-9
Positron emission tomography in thyroid cancer management.
Steven M. Larson (2002)
10.1089/thy.2009.1603
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances.
Martin Jean Schlumberger (2009)
10.1016/j.surg.2005.08.034
The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart.
Philip I. Haigh (2005)
10.1373/clinchem.2004.040501
Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays.
Carol M. Preissner (2005)
10.1089/thy.2006.0289
Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas.
Kenneth B. Ain (2007)
10.1210/jc.2005-0935
Familial risks for nonmedullary thyroid cancer.
Kari Hemminki (2005)
10.1089/thy.2009.0256
Pituitary metastases from follicular thyroid carcinoma.
Flavia Prodam (2010)
10.1007/s00761-010-1867-x
Schilddrüsenkarzinom – Klinik und Diagnostik
Wolfram Karges (2010)
10.1007/s00405-010-1207-1
Thyroid incidentalomas: to treat or not to treat
Narayanan Gopalakrishna Iyer (2010)
10.2967/jnumed.107.046599
Therapeutic Administration of 131I for Differentiated Thyroid Cancer: Radiation Dose to Ovaries and Outcome of Pregnancies
Jérôme-Philippe Garsi (2008)
10.1089/THY.2010.1624
Response to Pitoia and Ward
David S. Cooper (2010)
ATA THYROID NODULE/DTC GUIDELINES
M Toubeau (2004)
10.1016/j.surg.2008.08.004
Biological behavior and prognosis of familial papillary thyroid carcinoma.
Yasuhiro Ito (2009)
10.1210/JC.2007-1404
Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
Maria Grazia Castagna (2008)
Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 119:1135–1139
EJ Chisholm (2009)
The utility of I-123 pretherapy scan in 116 HAUGEN ET AL. I-131 radioiodine therapy for thyroid cancer
MK Chen (2012)
10.1016/S1041-892X(09)79356-4
Sonographically-Directed Neck Dissection for Recurrent Thyroid Carcinoma
Markus Gapany (2009)
The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma.
Robert D. Leeper (1973)
10.1097/01.mlg.0000191472.02720.1f
The utility of evaluating true vocal fold motion before thyroid surgery.
Tarik Y. Farrag (2006)
10.1038/nrc3037
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Mary Christine Hollander (2011)
10.1210/jc.2005-1705
The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies.
Francesco Boi (2006)
10.1002/dc.21423
FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples.
Cristina Aparecida Troques da Silveira Mitteldorf (2011)
10.1245/s10434-010-1358-8
Thyroid Isthmusectomy for Well-Differentiated Thyroid Cancer
Iain J Nixon (2010)
10.1002/cncr.10492
TNM residual tumor classification revisited.
Christian Wittekind (2002)
10.1007/s002590050477
Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma
Giuseppe Ronga (1999)
A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
Maseeh uz Zaman (2006)
10.1038/sj.bjc.6601319
Second primary malignancies in thyroid cancer patients
Corrado Rubino (2003)
10.1210/jcem.78.3.8126134
Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.
Steven I Sherman (1994)
10.1089/thy.2013.0244
Thyroglobulin in the washout fluid of lymph-node biopsy: what is its role in the follow-up of differentiated thyroid carcinoma?
Maria Roseneide dos Santos Torres (2014)
10.1016/j.radonc.2013.12.018
Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
Jian Tu (2014)
Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.
Martin Jean Schlumberger (1988)
10.1089/thy.2010.0232
Two weeks of a low-iodine diet are equivalent to 3 weeks for lowering urinary iodine and increasing thyroid radioactive iodine uptake.
Eveline Predebon Morsch (2011)
10.1002/lary.20140
Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis.
Steven R. Bomeli (2009)
10.1515/CCLM.2009.230
Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma
Luca Giovanella (2009)
Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer.
José Manuel Carril (1997)
10.4158/EP.13.5.521
Management of patients with low-risk papillary thyroid carcinoma.
Ian D. Hay (2007)
10.1016/j.surg.2007.09.003
Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery.
Alexandra I. Stavrakis (2007)
10.1089/105072502320288438
Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin.
Léonard Wartofsky (2002)
10.1136/jmg.2010.083790
DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome
Ingrid Slade (2011)
Surgeon-performed ultrasound in the management of thyroid malignancy.
Carmen C. Solórzano (2004)
10.1007/s00259-013-2521-9
Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study
Françoise Bonichon (2013)
10.2967/jnumed.107.042192
The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer: Long-Term Results of a Longitudinal Cohort Study
Martin A. Walter (2007)
10.1001/archsurg.139.4.390
Predicting outcome and directing therapy for papillary thyroid carcinoma.
Sendia Kim (2004)
10.1530/EJE-13-0386
Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation.
Camila Nascimento (2013)
10.1097/00000658-199809000-00005
The importance of surgeon experience for clinical and economic outcomes from thyroidectomy.
Julie Ann Sosa (1998)
10.7326/0003-4819-153-3-201008030-00010
The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods
Amir Qaseem (2010)
10.1089/thy.2010.0458
The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy and the sonographic differences between benign and malignant thyroid nodules 3 cm or larger.
Jung Hyun Yoon (2011)
10.1089/thy.2009.0155
The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution.
Constantine G. A. Theoharis (2009)
BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a metaanalysis
C Li (2012)
10.1515/CCLM.2011.155
Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays
Luca Giovanella (2011)
10.1089/thy.2009.0226
BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
Sang Yu Nam (2010)
10.7326/0003-4819-133-9-200011070-00011
Usefulness of Ultrasonography in the Management of Nodular Thyroid Disease
Ellen Marqusee (2000)
10.1089/thy.2006.16.55
The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules.
Rachel Redman (2006)
10.4158/EP.13.7.735
Value of repeating a nondiagnostic thyroid fine-needle aspiration biopsy.
Israel B Orija (2007)
10.1089/thy.2014.0594
The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012.
Juán Pablo Venables Brito (2015)
10.1210/jc.2011-2033
Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.
Carla Colombo (2012)
10.1245/s10434-015-4486-3
Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules
Jennifer L. Marti (2015)
10.1089/thy.2011.0081
MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases.
Ru-long Shen (2012)
Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period.
Ian D. Hay (1992)
10.1200/JCO.2007.16.0101
Are cancer-related decision aids effective? A systematic review and meta-analysis.
Mary Ann O’Brien (2009)
10.1007/s00761-010-1869-8
Nuklearmedizinische Therapie und Nachsorge des differenzierten Schilddrüsenkarzinoms: Status quo
Markus Dietlein (2010)
10.1007/s00268-008-9724-4
Neuromonitoring in Thyroid Surgery: Attitudes, Usage Patterns, and Predictors of Use Among Endocrine Surgeons
Cord Sturgeon (2008)
10.1111/cen.12130
Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Mayiluaganan Sabaretnam (2013)
10.1210/jc.2012-4172
Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.
Andrew N Hoofnagle (2013)
10.1007/s00268-017-4230-1
Ten-Year Follow-Up of a Randomized Clinical Trial of Total Thyroidectomy Versus Dunhill Operation Versus Bilateral Subtotal Thyroidectomy for Multinodular Non-toxic Goiter
Marcin Barczyński (2017)
10.1007/BF03344469
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens
Luca Chiovato (2003)
10.1007/s00259-008-0883-1
Guidelines for radioiodine therapy of differentiated thyroid cancer
Markus Luster (2008)
Calsolari MR 2014 Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid 24:533–536
PW Rosario (2014)
Impact of initial surgical treatment
M Duren (2000)
Changes in risk factors and Tumor Node Metastasis Page 280 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
H Karga (2011)
10.3174/ajnr.A1405
The Role of MR Imaging in Detecting Nodal Disease in Thyroidectomy Patients with Rising Thyroglobulin Levels
Sandra L. Kaplan (2009)
Impact of 131I-SPECT/CT images obtained with an integrated system Page 348 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
K Tharp (2004)
Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis.
Shodayu Takashima (1998)
10.1210/jc.2003-030231
Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma.
Carmen F A Eustatia-Rutten (2003)
10.1210/jcem.80.5.7744991
Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
Jacobo Díaz Pineda (1995)
10.1089/thy.2006.16.1019
The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer.
Kanchan Kulkarni (2006)
10.1016/j.surg.2012.08.019
Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?
Kathleen C Lee (2012)
10.1200/JCO.2013.49.1043
Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study.
Esther N Klein Hesselink (2013)
10.1586/era.12.96
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma
Marcia S. Brose (2012)
10.1056/NEJM199703273361301
Solid cancers after bone marrow transplantation.
Rochelle E. Curtis (1997)
10.1245/s10434-013-2897-6
Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence
David E Gyorki (2013)
10.1677/ERC-10-0292
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.
Camila Nascimento (2011)
Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
John Muratet (1998)
10.1016/j.surg.2013.04.068
The impact of surgical volume on patient outcomes following thyroid surgery.
Emad Kandil (2013)
10.1210/jc.2003-031041
Authors’ Response: A Consensus Report of the Role of Serum Thyroglobulin as a Monitoring Method for Low-Risk Patients with Papillary Thyroid Carcinoma
Ernest L. Mazzaferri (2003)
10.1007/s00268-001-0176-3
Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer
M. D. Andreas Machens (2002)
Risk stratification of patients with locally aggressive differentiated thyroid cancer
B Riemann (2010)
Longterm course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer
AS Alzahrani (2005)
10.1089/thy.2010.0331
A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases.
Concetto Regalbuto (2011)
10.1007/BF02306284
Patient satisfaction with decision-making for breast cancer therapy
Stephen M. Weiss (1996)
10.1210/jc.2007-2228
Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?
Georg Brabant (2008)
10.1056/NEJM198310203091601
Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.
Harry R. Maxon (1983)
Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large Page
M Shargorodsky (2006)
Change of serum antithyroglobulin antibody levels is useful for Page 329 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
WG Kim (2008)
10.1210/jcem.84.7.5827
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wenli Wang (1999)
10.1046/j.1365-2265.2000.00998.x
Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.
K M van Tol (2000)
10.1056/NEJMcp031436
The thyroid nodule.
Laszlo Hegedüs (1982)
10.1089/thy.2000.10.587
Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.
Kenneth B. Ain (2000)
10.1002/dc.10043
Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology.
Zubair W Baloch (2002)
10.1007/978-1-59259-995-0_52
Side Effects of 131I for Ablation and Treatment of Well-Differentiated Thyroid Carcinoma
Douglas Van Nostrand (2006)
10.1530/EJE-12-0954
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
Maria Grazia Castagna (2013)
10.1177/0194599811399556
What Are Thyroidectomy Patients Really Concerned About?
Lara Abdul-Sater (2011)
10.1097/00005537-200111000-00006
MRI detection of cervical metastasis from differentiated thyroid carcinoma.
Neil D. Gross (2001)
10.1080/15321810902782897
Correlation of Thyroglobulin Concentrations Measured by Radioimmunoassay and Immunoradiometric Assay and the Influence of Thyroglobulin Antibody
Marijana Stanojević (2009)
10.1210/jc.2004-0986
Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies.
Carole A. Spencer (2004)
The utility of I-123 pretherapy scan in 116 HAUGEN ET AL. I-131 radioiodine therapy for thyroid cancer
MK Chen (2012)
10.1158/1078-0432.CCR-07-4495
Identification of Genes Differentially Expressed in Benign versus Malignant Thyroid Tumors
Nijaguna B. Prasad (2008)
10.1089/thy.2010.0256
Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer.
Willieford Moses (2011)
10.1002/cncr.11442
Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality.
Sin-Ming Chow (2003)
10.1148/radiol.09091284
Can vascularity at power Doppler US help predict thyroid malignancy?
Hee Jung Moon (2010)
10.1111/j.1365-2265.1977.tb01340.x
The spectrum of thyroid disease in a community: the Whickham survey.
W Michael G Tunbridge (1977)
10.1089/thy.1998.8.15
Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules.
Daniele Danese (1998)
10.1210/jc.2002-020865
Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules.
Erik K. Alexander (2002)
10.1046/j.1365-2265.2003.01733.x
Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Jung-Min Koh (2003)
10.1245/s10434-013-3258-1
Lymph Node Ratio of the Central Compartment is a Significant Predictor for Locoregional Recurrence After Prophylactic Central Neck Dissection in Patients with Thyroid Papillary Carcinoma
In Sun Ryu (2013)
Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Joon Young Choi (2006)
10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9
Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group.
Steven I Sherman (1998)
10.1089/thy.2006.16.1121
Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.
Richard J Robbins (2006)
10.1002/lary.21119
Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement.
Gregory W. Randolph (2011)
10.1089/thy.2010.0355
Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy.
Akira Miyauchi (2011)
10.1111/j.1365-2265.2007.02907.x
Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
Annalisa Iervasi (2007)
Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
P. Perros (1999)
10.1002/cncy.21412
Should the thyroid AUS/FLUS category be further stratified by malignancy risk?
Michiya Nishino (2014)
10.1016/S0039-6060(05)80124-2
Prognostic factors and risk group analysis in follicular carcinoma of the thyroid.
Ashok R Shaha (1995)
Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
Annabelle David (2001)
10.1089/thy.2011.0522
Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.
Rosália do Prado Padovani (2012)
10.1001/archotol.134.5.536
Consensus statement on the classification and terminology of neck dissection.
Kevin Thomas Robbins (2008)
10.1210/JC.2007-1154
The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
Aaron P. Brown (2008)
Clinical experience with recombinant human
G Mariani (2000)
10.1089/thy.2012.0081
Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
Sophie Leboulleux (2012)
10.1210/jcem.87.4.8274
Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
Furio Pacini (2002)
10.1111/j.1365-2265.2006.02626.x
Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Christian Poetzi (2006)
10.1245/s10434-012-2391-6
Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?
Hilda Wong (2012)
10.1097/MLG.0b013e3180de4d49
Vocal fold immobility: a longitudinal analysis of etiology over 20 years.
Laura H. Swibel Rosenthal (2007)
10.1177/0194599811430898
Thyroidectomy-Related Malpractice Claims
Michael C Singer (2012)
10.1530/eje.0.1440005
Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Francesco Lippi (2001)
10.1210/jcem.87.4.8373
Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
Vahab Fatourechi (2002)
10.1530/EJE-11-0631
Approach to the patient with advanced differentiated thyroid cancer.
Martin Jean Schlumberger (2012)
10.1089/thy.2009.0338
Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
Carole A. Spencer (2010)
10.1089/thy.2014.0098
Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance.
Ralph P Tufano (2015)
10.1002/1097-0142(197209)30:3<848::AID-CNCR2820300336>3.0.CO;2-2
Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients.
Jeffrey A. Gottlieb (1972)
10.1002/1097-0142(197807)42:1<164::AID-CNCR2820420127>3.0.CO;2-P
Serum clearance rates of immunologically reactive thyroglobulin.
Paul Lo Gerfo (1978)
10.1677/erc.1.00826
Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications.
Arja Jukkola (2004)
10.1067/msy.2002.120657
Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma.
Sameer William Qubain (2002)
10.1067/msy.2099.102267
Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon.
Thomas J. Musholt (1999)
10.1210/jc.2012-3682
Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
Weiwei Cheng (2013)
10.1002/lary.21965
Effect of temporary vocal fold injection medialization on the rate of permanent medialization laryngoplasty in unilateral vocal fold paralysis patients.
Katherine C Yung (2011)
10.1111/j.1365-2265.2005.02228.x
Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
Anne Bachelot (2005)
10.1089/thy.2008.0339
Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma.
Douglas van Nostrand (2009)
10.1089/thy.1999.9.443
Detection of residual and recurrent thyroid cancer by radionuclide imaging.
Harry R. Maxon (1999)
10.1089/thy.2010.0178
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Robert Michael Tuttle (2010)
10.7326/0003-4819-129-8-199810150-00007
Outcome after Treatment of High-Risk Papillary and Non-Hurthle-Cell Follicular Thyroid Carcinoma
Tracy A. Taylor (1998)
10.1002/cncy.20095
HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
Paul J Lappinga (2010)
10.1210/jc.2013-4048
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Xiaoli Liu (2014)
10.1093/annonc/mdp025
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
Giuseppe di Lorenzo (2009)
10.1089/thy.2013.0650
Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
Pedro Weslley Rosario (2014)
10.1002/(SICI)1097-0142(19971215)80:12<2268::AID-CNCR8>3.0.CO;2-Q
Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma.
Hiroyuki Yamashita (1997)
10.1016/j.jamcollsurg.2012.12.036
Does enrollment in cancer trials improve survival?
Christopher J. Chow (2013)
10.1210/jcem.86.11.8055
Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration.
Milena Braga (2001)
10.1056/NEJM199411103311901
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.
Clark T. Sawin (1994)
Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral Page 307 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Raffaelli (2012)
10.1007/s00423-010-0696-0
Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study
Andreas Hillenbrand (2010)
10.1007/s12149-007-0179-8
Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma
Jong Jin Lee (2008)
10.1089/thy.2008.0080
Radiofrequency ablation of hepatic metastases from thyroid carcinoma.
Marieke W J L A E Wertenbroek (2008)
10.1111/j.1365-2265.2006.02612.x
Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT.
Han-Sin Jeong (2006)
10.2214/ajr.175.6.1751619
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year.
Thierry de Baere (2000)
10.1016/j.jamcollsurg.2012.05.027
Intraoperative pathologic examination in the era of molecular testing for differentiated thyroid cancer.
Kelly L. Mccoy (2012)
10.1002/1097-0142(197602)37:2+<1111::AID-CNCR2820370821>3.0.CO;2-E
The effects of gonadal irradiation in clinical radiation therapy: a review.
Clarence C. Lushbaugh (1976)
10.1097/01.sla.0000157317.60536.08
Prognostic Importance of Histologic Vascular Invasion in Papillary Thyroid Carcinoma
Laura Falvo (2005)
Individualized dosimetry in the management of metastatic differentiated thyroid cancer.
Carlo Chiesa (2009)
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
Richard J Robbins (2002)
10.1007/s12020-009-9262-3
Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings
Kamile Gul (2009)
10.3349/ymj.2014.55.2.339
Thyroid Nodules with Macrocalcification: Sonographic Findings Predictive of Malignancy
Yun Joo Park (2014)
Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123-1129 Page 314 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
A D'Avanzo (2004)
10.1001/jamaoto.2014.1
Current thyroid cancer trends in the United States.
Lindsey Davies (2014)
10.1007/978-0-387-87666-5_4
Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance
Jeffrey F Krane (2015)
10.1038/sj.bjc.6602551
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration
Andrew M Wardley (2005)
10.1111/j.1365-2265.2007.02800.x
Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
Maria Rosaria Sapio (2007)
10.1016/j.metabol.2010.06.004
Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Helen Karga (2011)
10.1001/archinte.1990.00390130107016
The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds.
Jaap F. Hamming (1990)
10.1245/s10434-010-1129-6
The BRAF Mutation Is Predictive of Aggressive Clinicopathological Characteristics in Papillary Thyroid Microcarcinoma
Kuai-lu Lin (2010)
10.1016/j.surg.2009.09.011
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
Linwah Yip (2009)
10.1245/s10434-012-2851-z
Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases
Xiangqian Zheng (2012)
10.1002/CNCR.23116
Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation.
Leila Yassa (2007)
BRAF status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma
JD Prescott (2012)
Recurrent laryngeal nerve dysfunction ATA THYROID NODULE/DTC GUIDELINES 107 following carotid endarterectomy
AJ Curran (1997)
Skeletalrelated events due to bone metastases from differentiated thyroid cancer
A Farooki (2012)
10.7326/0003-4819-155-8-201110180-00009
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
Penny Whiting (2011)
10.1097/SLA.0b013e3180f61adc
Fine-Needle Aspiration May Miss a Third of All Malignancy in Palpable Thyroid Nodules: A Comprehensive Literature Review
Yoon Y. Tee (2007)
10.1159/000339959
The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis
Massimo Bongiovanni (2012)
Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome
SI Sherman (1998)
10.1089/thy.2014.0418
A systematic review of randomized controlled trials for management of persistent post-treatment fatigue in thyroid cancer survivors.
Joshua To (2015)
10.1210/jc.2010-2762
Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.
Carole A. Spencer (2011)
10.1530/EJE-09-0761
Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy.
Guia Vannucchi (2010)
10.1007/s00259-011-1841-x
Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl
Helge Hebestreit (2011)
10.1007/s00104-009-1884-8
Minimal-invasives follikuläres Schilddrüsenkarzinom
Marek Hermann (2009)
10.1016/j.surg.2006.08.001
Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer.
Mark S. Sywak (2006)
10.1097/01.sla.0000250451.59685.67
Total Thyroidectomy Plus Neck Dissection in Differentiated Papillary Thyroid Carcinoma Patients: Pattern of Nodal Metastasis, Morbidity, Recurrence, and Postoperative Levels of Serum Parathyroid Hormone
Jong-Lyel Roh (2007)
10.1210/jc.2012-1533
The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients.
Richard Charles Webb (2012)
10.1111/j.1365-2265.2006.02664.x
Natural course of benign thyroid nodules in a moderately iodine-deficient area.
Murat Faik Erdoğan (2006)
10.1089/thy.1997.7.273
131I therapy for elevated thyroglobulin levels.
Martin Jean Schlumberger (1997)
10.1097/RLU.0b013e3181e05fe3
Visualization of Thyroglossal Duct Cyst in Differentiated Thyroid Cancer Patient
Dong Li (2010)
10.1016/j.surg.2013.05.015
Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology.
Rohtesh S Mehta (2013)
10.1530/eje.0.1480019
Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Massimo Torlontano (2003)
10.1097/00003072-197810000-00009
Endogenous Serum TSH Levels and Metastatic Survey Scans in Thyroid Cancer Patients Using Triiodothyronine Withdrawal
N. D. T. Martin (1978)
10.1016/j.jamcollsurg.2004.10.031
A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.
Emin Yildirim (2005)
10.1089/thy.2012.0369
Risk stratification of follicular variant of papillary thyroid carcinoma.
Marina Vivero (2013)
10.1245/s10434-012-2614-x
BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer
Martha A. Zeiger (2012)
10.1089/thy.2011.0011
Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression.
Geneviève Rondeau (2011)
10.1001/archotol.126.3.309
Prognostic importance of vascular invasion in papillary thyroid carcinoma.
Rebecca Ellis Gardner (2000)
Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TIRADS). Head Neck 35:541–547
SP Cheng (2013)
10.1097/SLA.0b013e318230036d
Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated?: An Analysis of 18,445 Cases
Xiao-min Yu (2011)
10.1507/ENDOCRJ.EJ12-0256
Clinical prognostic index for recurrence of papillary thyroid carcinoma including intraoperative findings.
Kwang Min Kim (2013)
10.1210/jcem.85.1.6310
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
Anne F. Cailleux (2000)
10.1210/jc.2006-0690
Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography.
Mary C Frates (2006)
10.1089/thy.1999.9.105
Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer.
Andrea Frasoldati (1999)
10.1210/jcem.87.2.8182
Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).
Joseph G. Hollowell (2002)
10.1530/EJE-07-0603
Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma.
Stéphane Bardet (2008)
10.1210/jc.2005-0492
A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later.
Richard T. Kloos (2005)
10.1089/thy.2012.0183
Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Jonathan Hugo (2012)
Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid Page 308 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
C Gouveia (2013)
10.1111/j.1365-2265.1987.tb00846.x
Serial serum thyroglobulin measurements in the management of differentiated thyroid carcinoma.
E. G. Black (1987)
10.1210/jcem.83.4.4683
Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma.
Carole A. Spencer (1998)
10.1016/j.surg.2012.08.039
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.
Jason D. Prescott (2012)
Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing ATA THYROID NODULE/DTC GUIDELINES 105 radioiodine ablation for differentiated thyroid cancer
D Yoo (2012)
Long-term thyrotropinsuppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma
M Shargorodsky (2006)
10.1002/hed.21079
Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma.
Gary L Clayman (2009)
10.1007/s002590050158
Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
Markus Dietlein (1997)
10.1089/thy.2011.0192
In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
Haggi Mazeh (2012)
10.1590/S0004-27302004000400008
Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance.
Pedro Weslley Rosario (2004)
10.1245/s10434-010-1220-z
The Learning Curve for Robotic Thyroidectomy: A Multicenter Study
Jandee Lee (2010)
10.1089/thy.2013.0049
American Thyroid Association statement on outpatient thyroidectomy.
David J Terris (2013)
10.1007/s00259-010-1532-z
The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging
Walter Jentzen (2010)
10.1089/thy.2011.0203
The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer.
Ming-Kai Chen (2012)
10.1002/(SICI)1097-0142(19970615)79:12<2414::AID-CNCR18>3.0.CO;2-U
A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example.
James Brierley (1997)
Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Wim J. G. Oyen (2000)
10.1089/thy.2013.0062
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.
Donald A. Mcleod (2014)
10.1530/EJE-07-0399
The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.
Ha T. T. Phan (2008)
10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X
Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas.
Atsuhiko Sakamoto (1983)
10.1245/s10434-013-3406-7
A Systematic Review and Meta-analysis Comparing Surgically-Related Complications between Robotic-Assisted Thyroidectomy and Conventional Open Thyroidectomy
Brian Hung-Hin Lang (2013)
10.1007/BF03345495
Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer
Ali S Alzahrani (2002)
10.1097/01.mnh.0000071241.54690.6f
Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates
Maroun Karam (2003)
10.1007/s00268-008-9600-2
Predictive Value of Sonographic Features in Preoperative Evaluation of Malignant Thyroid Nodules in a Multinodular Goiter
Artür Salmaslıoğlu (2008)
10.1016/J.JSS.2007.09.020
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer?
Daniel Repplinger (2008)
10.1016/S1041-892X(08)79163-7
Extent of Surgery Affects Survival for Papillary Thyroid Cancer
Markus Gapany (2008)
Surgical treatment of advanced thyroid carcinoma with aerodigestive invasion
JH Ge (2004)
Thyroid lobe ablation with iodine-131I 106 HAUGEN ET AL. in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities
L Giovanella (2013)
BRAF mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer
GM Howell (2013)
Long-term outcomes of injection laryngoplasty in patients with potentially recoverable vocal fold paralysis. Laryngoscope 120:2237–2240
LC Arviso (2010)
10.1016/j.ejca.2012.08.002
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Allan Lipton (2012)
Recurrent laryngeal nerve dysfunction following carotid endarterectomy.
Aongus Curran (1997)
10.1089/thy.2012.0493
Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: a systematic review and meta-analysis.
Antoine Eskander (2013)
10.1007/s00268-013-2089-3
Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma
Dana M. Hartl (2013)
10.1056/nejm-jw.NA37174
Natural History of Benign Thyroid Nodules
Allan S. Brett (2015)
10.1001/jamaoto.2013.4501
Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Christopher J Gouveia (2013)
10.1210/jc.2010-1082
Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
Suk Kyeong Kim (2011)
10.1309/07TL3V58337TXHMC
Comparison of thyroid fine-needle aspiration and core needle biopsy.
Andrew A Renshaw (2007)
10.1111/j.1365-2265.2006.02515.x
Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Ying ying Liu (2006)
10.1002/hed.21362
Differential effects between cyclooxygenase-2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines.
Seokwoo Park (2010)
10.1089/thy.2007.0014
Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings.
Yasuhiro Ito (2007)
10.1007/s00259-009-1303-x
Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience
Frederik A. Verburg (2009)
10.1016/j.surg.2010.09.019
Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer.
David T. Hughes (2010)
10.1007/s00259-004-1460-x
Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma
Seyfettin Ilgan (2004)
10.1089/thy.2006.16.1145
Positive predictive value of detectable stimulated tg during the first year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months.
Maristane Mendes Andrade Valadão (2006)
10.1111/j.1749-4486.2006.01291.x
Exploring the relationship between severity of dysphonia and voice-related quality of life.
Sherrie Jones (2006)
10.4158/EP10060.OR
Encapsulated classic and follicular variants of papillary thyroid carcinoma: comparative clinicopathologic study.
Zubair W Baloch (2010)
10.1155/2012/481568
Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
Fabián Pitoia (2012)
Sameday thyroidectomy: a review of practice patterns and outcomes for 1,168 procedures in New York State
CT Tuggle (2011)
10.1016/S0188-4409(02)00394-6
Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma.
R Sánchez (2002)
Second primary Page 363 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
S Subramanian (2007)
The treatment and prognosis of Hurthle cell follicular thyroid carcinoma compared with its non-Hurthle cell counterpart. Surgery
PI Haigh (2005)
10.1089/thy.2009.0187
Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Jandee Lee (2010)
10.1002/bjs.9676
Importance of in situ preservation of parathyroid glands during total thyroidectomy.
L Lorente-Poch (2015)
10.1245/s10434-010-1137-6
Prophylactic Central Neck Dissection and Local Recurrence in Papillary Thyroid Cancer: A Meta-analysis
Tarek Zetoune (2010)
10.1210/jc.2004-1771
Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Tae Yong Kim (2005)
10.1097/01.sla.0000250445.92336.2a
Staging Systems for Papillary Thyroid Carcinoma: A Review and Comparison
Brian H H Lang (2007)
10.1002/1097-0142(20010715)92:2<225::AID-CNCR1313>3.0.CO;2-B
The development of breast carcinoma in women with thyroid carcinoma.
Amy Y. Chen (2001)
10.1245/s10434-009-0644-9
The Role of BRAFV600E Mutation and Ultrasonography for the Surgical Management of a Thyroid Nodule Suspicious for Papillary Thyroid Carcinoma on Cytology
Hee Jung Moon (2009)
10.1245/s10434-011-2129-x
Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients
Hadiza S. Kazaure (2011)
10.1056/NEJM197401242900404
Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.
Jeffrey A. Gottlieb (1974)
10.1089/thy.1998.8.283
Ultrasound-guided fine-needle aspiration biopsy of thyroid masses.
C Carmeci (1998)
10.1002/cncy.20195
Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multi-institutional study.
Massimo Bongiovanni (2012)
10.1210/jc.2011-1740
Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).
Carole A. Spencer (2011)
10.1210/jc.2008-1747
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
Sophie Leboulleux (2009)
10.1016/S0360-3016(03)00199-8
Is there a role for radiation therapy in the management of Hürthle cell carcinoma?
Robert L. Foote (2003)
10.1210/jc.2005-1322
Survival and death causes in differentiated thyroid carcinoma.
Carmen F A Eustatia-Rutten (2006)
Utility of the radioiodine whole-body retention at 48 hours for Page 356 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
D Van Nostrand (2009)
10.1038/nrendo.2010.17
Thyroid gland: Revised guidelines for the management of thyroid cancer
Kristien Boelaert (2010)
10.1089/thy.2013.0018
Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma.
Brooke E. Howitt (2013)
Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome.
Partha Sinha (2011)
10.1097/SLA.0b013e31814697d9
Extent of Surgery Affects Survival for Papillary Thyroid Cancer
Karl Y. Bilimoria (2007)
10.1007/s00268-006-0722-0
Lateral and Mediastinal Lymph Node Dissection in Differentiated Thyroid Carcinoma: Indications, Benefits, and Risks
Yasuhiro Ito (2006)
10.1210/jc.2007-0444
Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer.
Sophie Leboulleux (2007)
10.1007/s00268-005-0113-y
Clinical Significance of Metastasis to the Central Compartment from Papillary Microcarcinoma of the Thyroid
Yasuhiro Ito (2005)
10.7863/JUM.2009.28.12.1685
Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas.
Dae Sik Kim (2009)
10.1159/000334214
Timing of Repeat Thyroid Fine-Needle Aspiration in the Management of Thyroid Nodules
Remmi S Singh (2011)
10.1002/(SICI)1097-0339(199702)16:2<122::AID-DC5>3.0.CO;2-J
Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women.
Edith F. Marley (1997)
10.1016/S0002-9610(01)00843-1
The clinicopathological significance of histologic vascular invasion in differentiated thyroid carcinoma.
Toshirou Nishida (2002)
10.1089/thy.2012.0368
Systematic use of recurrent laryngeal nerve neuromonitoring changes the operative strategy in planned bilateral thyroidectomy.
Samira M. Sadowski (2013)
10.1016/S1470-2045(08)70155-4
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study).
Riccardo Antonio Lencioni (2008)
10.1503/cjs.023209
Incidental thyroid "PETomas": clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake.
Hidefumi Nishimori (2011)
10.1002/lary.23923
National trends in thyroid surgery and the effect of volume on short-term outcomes.
Myriam Loyo (2013)
10.1054/bjoc.2001.1832
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer
Giovanni Vitale (2001)
10.1097/PAS.0b013e3181c46677
Papillary Thyroid Carcinoma With Prominent Hobnail Features: A New Aggressive Variant of Moderately Differentiated Papillary Carcinoma. A Clinicopathologic, Immunohistochemical, and Molecular Study of Eight Cases
Sofia Asioli (2010)
Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid 22:332–333
PW Rosario (2012)
Is (18)Ffluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 22:165–172
D Deandreis (2012)
Impact of 131I-SPECT/CT images obtained with an integrated system Page 348 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
K Tharp (2004)
BRAF mutation and p27 kip1 expression in papillary carcinomas of the thyroid
V Rodolico (2007)
10.7326/0003-4819-126-3-199702010-00009
Thyroid Incidentalomas: Management Approaches to Nonpalpable Nodules Discovered Incidentally on Thyroid Imaging
G. H. Tan (1997)
10.1002/cncr.21055
The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma.
Andreas Machens (2005)
10.1046/j.1365-2265.2003.01912.x
Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings.
Il Seong Nam-Goong (2004)
10.1038/ncpendmet0020
Thyroid-hormone therapy and thyroid cancer: a reassessment
Bernadette Biondi (2005)
10.1007/s002680010214
Impact of Initial Surgical Treatment on Survival of Patients with Differentiated Thyroid Cancer: Experience of an Endocrine Surgery Center in an Iodine-deficient Region
Mete Duren (2014)
10.1089/thy.1998.8.1087
Value of re-aspirations in benign nodular thyroid disease.
Murat Faik Erdoğan (1998)
10.1089/thy.2005.15.251
Distinct diagnostic criteria for ultrasonographic examination of papillary thyroid carcinoma: a multicenter study.
Hiroki Shimura (2005)
10.1172/JCI46382
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Debyani Chakravarty (2011)
10.1016/j.humpath.2006.08.001
Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma.
Jean Jacques Michels (2007)
10.1097/PPO.0b013e31824b436e
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.
Ragini Reiney Kudchadkar (2012)
10.4158/EP13029.OR
Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer?
Lindsay Bischoff (2013)
10.1148/radiol.2402050807
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.
Thierry de Baere (2006)
10.1158/1055-9965.EPI-13-0242
The Clinical and Economic Burden of a Sustained Increase in Thyroid Cancer Incidence
Briseis Aschebrook-Kilfoy (2013)
10.1309/AJCPPHLWMI3JV4LA
The Bethesda System For Reporting Thyroid Cytopathology.
Edmund S Cibas (2009)
10.1089/thy.2010.0145
Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.
Pedro Weslley Rosario (2011)
10.1002/hed.23371
Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma.
Jin Chung (2014)
10.1210/jc.2014-4332
Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ewa Ruel (2015)
10.1089/thy.1999.9.435
Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Carole A. Spencer (1999)
10.1002/cncr.24837
Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial.
Damian E Dupuy (2010)
10.1210/jc.2007-1043
Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules.
Fernando Moreno Sebastianes (2007)
10.1046/j.1365-2265.2002.01592.x
Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation.
J-K Chung (2002)
10.1002/lary.22426
Prevalence and causes of dysphonia in a large treatment-seeking population.
Seth M. Cohen (2012)
10.1111/j.1398-9995.2009.02083.x
Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies.
Jan L Brozek (2009)
Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral Page 307 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
M Raffaelli (2012)
Is (18)Ffluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid
D Deandreis (2012)
Encapsulated follicular variant of papillary thyroid carcinoma.
Jennifer Leigh Hunt (2002)
10.1016/J.JAMCOLLSURG.2012.06.320
Hemithyroidectomy: a meta-analysis of postoperative need for hormone replacement and complications
Salem I. Noureldine (2012)
10.1007/s002590050223
Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma
Françoise Aubène Leger (1998)
10.1089/105072504323150778
Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome.
Alessandra D'Avanzo (2004)
10.1111/j.1365-2559.2004.01729.x
Extensive vascular invasion is a marker of risk of relapse in encapsulated non-Hürthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11-year median follow-up.
Paola Collini (2004)
10.1530/EJE-08-0669
Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.
Marco Chianelli (2009)
10.1097/01.sla.0000262785.46403.9b
Staging Systems for Papillary Thyroid Carcinoma: A Study of 2 Tertiary Referral Centers
Brian H H Lang (2007)
10.1210/jcem.83.11.5215
Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses.
Flávio Zelmanovitz (1998)
10.1089/thy.2013.0573
Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.
Carrie Lubitz (2014)
10.1016/j.surg.2008.09.006
Reliability of benign fine needle aspiration cytology of large thyroid nodules.
John R Porterfield (2008)
10.1089/thy.2011.0163
The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
Young Joo Park (2012)
10.4158/EP13330.OR
Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology.
R. Mack Harrell (2014)
10.1016/J.YOTO.2012.02.028
Efficacy of Ultrasound-Guided Percutaneous Ethanol Injection Treatment in Patients with a Limited Number of Metastatic Cervical Lymph Nodes from Papillary Thyroid Carcinoma
Markus Gapany (2012)
The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell
PI Haigh (2005)
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
Amer Shammas (2007)
Clinical practice guideline: improving voice outcomes after thyroid surgery
SS Chandrasekhar (2013)
The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in Page 301 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
F Boi (2006)
10.1111/j.1365-2265.1978.tb02201.x
Thyroglobulin of varying molecular sizes with different disappearance rates in plasma following subtotal thyroidectomy.
Ulla Feldt-Rasmussen (1978)
10.1016/j.amjsurg.2006.10.009
The evaluation of the causes of subjective voice disturbances after thyroid surgery.
Lutfi Soylu (2007)
10.1186/1756-6614-3-9
Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
Aleksandra Kukulska (2010)
10.1136/pmj.78.916.92
Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer
Louiza Vini (2002)
10.1210/jc.2003-031521
Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases.
Massimo Torlontano (2004)
10.4158/EP.10.3.269
Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules.
Roberto Valcavi (2004)
10.1016/j.otohns.2007.03.001
Transient hypoparathyroidism following thyroidectomy: A prospective study and multivariate analysis of 604 consecutive patients
Ottavio Cavicchi (2007)
10.1016/j.beem.2013.07.003
Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer.
Carole A. Spencer (2013)
10.1200/JCO.2004.03.097
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study.
Matthew P. Goetz (2004)
10.3949/ccjm.43.4.207
The many appearances of papillary carcinoma of the thyroid.
William A. Hawk (1976)
10.1258/acb.2011.010248
Concordance between thyroglobulin antibody assays
Kevin P Taylor (2011)
Pediatric thyroid nodules: disease demographics and clinical management as determined by fine needle aspiration biopsy.
Stephen Spencer Raab (1995)
10.1089/thy.2009.0464
Enlarged benign-appearing cervical lymph nodes by ultrasonography are associated with increased likelihood of cancer somewhere within the thyroid in patients undergoing thyroid nodule evaluation.
Kathleen E Hands (2010)
10.1089/105072504322783821
Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases.
Lourdes R. Ylagan (2004)
10.1089/105072501750159714
Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens.
Avi Kelman (2001)
10.1007/s00268-006-0907-6
Central Lymph Node Dissection in Differentiated Thyroid Cancer
Matthew L. White (2006)
Level VI lymph node dissection does not decrease radioiodine uptake in patients undergoing ATA THYROID NODULE/DTC GUIDELINES 105 radioiodine ablation for differentiated thyroid cancer
D Yoo (2012)
Preoperative FDG-PET imaging to assess the ma 100 HAUGEN ET AL. lignant potential of follicular neoplasms of the thyroid
RB Smith (2008)
Measurement of serum TSH and thyroid hormones in the ATA THYROID NODULE/DTC GUIDELINES 117 management of treatment of thyroid carcinoma with radioiodine
CJ Edmonds (1977)
The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell
PI Haigh (2005)
10.1210/jc.2003-030550
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
R. Elisei (2004)
Calsolari MR 2014 Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid
PW Rosario (2014)
10.1245/s10434-014-3846-8
Total Thyroidectomy is Associated with Increased Risk of Complications for Low- and High-Volume Surgeons
Mba Adam Hauch MD (2014)
10.1016/j.clon.2012.01.001
Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo.
Usha Mallick (2012)
10.1001/jama.2013.3190
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing (2013)
10.1210/jc.2005-0671
Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas.
Carole A. Spencer (2005)
Role of prophylactic central neck dissection in cN0 papillary thyroid cancer.
S. R. R. Costa (2009)
10.1089/thy.2009.0450
Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study.
Cüneyd Anıl (2010)
10.1007/s00268-012-1431-5
Evaluation of Postoperative Radioactive Iodine Scans in Patients who Underwent Prophylactic Central Lymph Node Dissection
Amanda M. Laird (2012)
Frequency and clinical importance of anti-Tg auto-antibodies (ATG).
Allah Rakha Adil (2003)
10.1089/105072502760258686
Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma.
Anne Bachelot (2002)
10.1530/EJE-13-0825
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
M.-H. Massicotte (2014)
10.1111/j.1365-2265.2004.02065.x
Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation.
Eun Sook Kim (2004)
10.1159/000341362
Large Discrepancy in the Results of Sensitive Measurements of Thyroglobulin Antibodies in the Follow-Up on Thyroid Cancer: A Diagnostic Dilemma
Birte Nygaard (2012)
10.1530/EJE-06-0616
Usefulness of repeated fine-needle cytology in the follow-up of non-operated thyroid nodules.
Frédéric Illouz (2007)
10.1016/j.surg.2008.08.035
Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.
Ian D. Hay (2008)
10.1111/j.1749-4486.2010.02085.x
Treatment and prognostic factors of papillary thyroid microcarcinoma.
Davide Giordano (2010)
10.1210/jc.2013-3734
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Miguel Melo (2014)
10.1210/jcem.81.12.8954034
Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer.
Pascal Pujol (1996)
10.1017/S0022215100144731
Are pre-operative vocal fold checks necessary?
K M Green (1999)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Elizabeth A. Eisenhauer (2009)
10.1007/s00259-010-1657-0
Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up
Frank Berger (2010)
10.1210/jc.2010-2298
The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation.
Ji Hye Yim (2011)
10.1016/S0002-9610(99)80331-6
Differentiated carcinoma of the thyroid with extrathyroidal extension.
Peter E. Andersen (1995)
10.1007/s00259-004-1565-2
Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma
Kevin W. Tharp (2004)
10.4158/EP10206.ED
Surgery of well-differentiated thyroid carcinoma: the pendulum swings back in the central neck.
Gregory W. Randolph (2010)
10.1097/00006231-200411000-00002
Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake
Pedro Weslley Rosario (2004)
Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation.
Perry Grigsby (2004)
10.1016/j.ecl.2007.04.009
Thyroid nodules: clinical importance, assessment, and treatment.
H. Gharib (2007)
10.1007/s00268-014-2498-y
Revisiting the Guidelines Issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: A Gradual Move Towards Consensus Between Japanese and Western Practice in the Management of Thyroid Carcinoma
Hiroshi E. Takami (2014)
10.1097/01.rlu.0000162602.48653.54
Differentiated Thyroid Carcinoma in Children and Young Adults: Evaluation of Response to Treatment
Nir Hod (2005)
10.1016/S1072-7515(03)00332-6
Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.
Margo C Shoup (2003)
Vocal cord paralysis.
William C. Thornell (1963)
10.1089/thy.2013.0011
Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Fabián Pitoia (2013)
10.1002/cncr.26638
Insular thyroid cancer: a population-level analysis of patient characteristics and predictors of survival.
Hadiza S. Kazaure (2012)
10.1002/lary.21227
Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer.
Harry S. Hwang (2011)
10.1097/00000478-198801000-00003
Prognostic Implications of the Tall Cell Variant of Papillary Thyroid Carcinoma
Teresa L. Johnson (1988)
10.1007/s00268-009-9940-6
Clinicopathologic Characteristics and Prognosis of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma in Japan: An 18-Year Experience at a Single Institution
Mitsuhiro Fukushima (2009)
10.1007/s12022-006-0001-5
Radiation-induced thyroid cancer: What we have learned from Chernobyl
Yuri E Nikiforov (2006)
The role of [18F]-2fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature
D Vriens (2011)
Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic 128 HAUGEN ET AL. radioiodine whole body scan
M Chao (2010)
Thyroid carcinoma. Lancet 361:501–511
SI Sherman (2003)
10.1001/jama.285.9.1131
Moral Wounds: Complicated Complications
Shari Munch (2001)
10.1089/thy.2009.1606
Controversies in the surgical management of newly diagnosed and recurrent/residual thyroid cancer.
Rebecca S. Sippel (2009)
10.1002/14651858.CD001431.pub5
Decision aids for people facing health treatment or screening decisions.
Dawn Stacey (2017)
10.1089/thy.2009.0159
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.
Sally E. Carty (2009)
10.1309/P7QL-16KQ-QLF4-XW0M
Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma.
John Kwok-cheung Chan (2002)
10.1210/jc.2005-1185
Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Massimo Torlontano (2006)
10.1677/erc.1.00880
Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Barbara Jarzab (2005)
10.1002/cncr.11488
Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years.
Robert R McWilliams (2003)
Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients.
Martin Jean Schlumberger (1996)
10.1507/endocrj.46.209
Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors.
Iwao Sugitani (1999)
Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large Page 350 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Shargorodsky (2006)
10.1245/s10434-010-1141-x
Sentinel Lymph Node Biopsy for Papillary Thyroid Cancer: 12 Years of Experience at a Single Institution
Deborah K Cunningham (2010)
Espinosa de los monteros
Rafael Cañada Quesada (2000)
First treatment activity and outcome of radioiodine therapy in thyroid cancer patients with metastases in lymph nodes: mathematical correlation and clinical implications.
Kozak Ov (2006)
10.1210/jc.2012-1775
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
R. Elisei (2012)
10.1210/jc.2005-0285
Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.
Sophie Leboulleux (2005)
10.1002/hed.21142
Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings.
Young Joo Park (2009)
Clinical practice. Subclinical hyperthyroidism.
Anthony D. Toft (2001)
10.2967/jnumed.107.047159
Optimized 124I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer
Walter Jentzen (2008)
10.1186/1742-6413-5-1
Utility of Thyroglobulin measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma
Zubair W Baloch (2008)
10.1210/JC.2007-2215
Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.
Megan R Haymart (2008)
Follicular thyroid carcinoma: histology and prognosis. Cancer 100:1123-1129 Page 314 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y
A D'Avanzo (2004)
Treatment of scannegative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone
AZ Rudavsky (1997)
Woodson Page 313 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Barczynski (2013)
10.1111/cen.12515
Guidelines for the management of thyroid cancer.
P. Perros (2014)
Management of invasive well-differentiated thyroid cancer an American Head and Neck society consensus statement. Head NeckIn press
ML Shindo (2014)
10.1210/jc.2010-2708
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
M Brassard (2011)
10.1097/00004728-200301000-00004
Esophageal Invasion by Thyroid Carcinomas: Prediction Using Magnetic Resonance Imaging
Jichen Wang (2003)
10.1007/s00423-009-0470-3
The false-negative rate of fine-needle aspiration cytology for diagnosing thyroid carcinoma in thyroid nodules
Bekir Kuru (2009)
Persistent disease and recurrence in differentiated thyroid cancer patients with Page 328 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
C Nascimento (2011)
10.1210/jc.2012-4137
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Eleonora Molinaro (2013)
10.1055/s-0030-1254132
Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients.
Frederik Anton Verburg (2010)
10.1200/jco.2014.32.18_suppl.lba6008
A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).
Makoto Tahara (2014)
10.1148/radiol.2261021292
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.
Patrick M. M. Bossuyt (2003)
Exploring the relationship between severity of dysphonia and voicerelated quality of life
SM Jones (2006)
10.1002/(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2
Management of the patient with progressive radioiodine non-responsive disease.
B Haugen (1999)
10.1186/1748-5908-8-49
Guideline adaptation and implementation planning: a prospective observational study
Margaret B. de Harrison (2013)
10.1007/s00268-012-1476-5
Skip Lateral Neck Node Metastases in Papillary Thyroid Carcinoma
Jae Hyun Park (2012)
10.1089/10507250152484583
Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma.
Lilah F. Morris (2001)
10.1016/S0140-6736(96)01073-2
Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications
Robert Brian Haynes (1996)
10.1038/modpathol.2010.117
Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression
Sofia Asioli (2010)
10.1089/thy.2011.0121
In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival.
Mauricio A. Moreno (2012)
10.1210/jc.2003-030298
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Daniele Barbaro (2003)
10.1210/jc.2003-031967
Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer.
Priya Chinnappa (2004)
10.1097/00000658-200205000-00007
Implications of Follicular Neoplasms, Atypia, and Lesions Suspicious for Malignancy Diagnosed by Fine-Needle Aspiration of Thyroid Nodules
Richard E Goldstein (2002)
10.1210/jc.2011-2864
The impact of age and gender on papillary thyroid cancer survival.
Jacqueline Jonklaas (2012)
10.1089/thy.2012.0608
A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy.
Brian H H Lang (2013)
10.1046/j.1365-2168.2002.02068.x
Impact of timing on completion thyroidectomy for thyroid cancer.
M. P. Tan (2002)
AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma.
Petri E. Voutilainen (2003)
10.1158/1078-0432.CCR-10-0994
Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
Laurie L. Carr (2010)
10.1038/nrclinonc.2009.188
Stereotactic body radiation therapy: a novel treatment modality
Simon S Lo (2010)
10.1530/ERC-13-0210
Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu (2013)
10.1089/thy.1999.9.421
An overview of the management of papillary and follicular thyroid carcinoma.
Ernest L. Mazzaferri (1999)
10.1007/s11912-011-0180-1
Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Tarek Mekhail (2011)
Survival time and "cure" in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy.
William H. Beierwaltes (1982)
10.3275/8998
Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: Direct comparison and network meta-analyses
Yi Fang (2013)
10.1245/s10434-013-3125-0
A Meta-analysis of the Effect of Prophylactic Central Compartment Neck Dissection on Locoregional Recurrence Rates in Patients with Papillary Thyroid Cancer
Tracy S. Wang (2013)
10.1210/jc.2013-3483
Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
Dennis Vriens (2014)
10.1089/thy.2006.16.1273
Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis.
Shu-Hua Huang (2006)
10.1210/jc.2011-0494
Efficacy of Dosimetric Versus Empiric Prescribed Activity of 131I for Therapy of Differentiated Thyroid Cancer
Joanna Kłubo-Gwieździńska (2011)
10.1007/s00423-012-1032-7
IONM-guided goiter surgery leading to two-stage thyroidectomy—indication and results
Magnus Melin (2012)
10.1002/cncr.21825
Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
Ronald A. Ghossein (2006)
10.1097/00000478-199610000-00005
Encapsulated columnar-cell neoplasms of the thyroid. A report of four cases suggesting a favorable prognosis.
Harry L. Evans (1996)
10.1097/00005537-200312000-00008
Clinical course of thyroid carcinoma after neck dissection.
Manish D. Shah (2003)
Post I-131 ATA THYROID NODULE/DTC GUIDELINES 119 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution
PW Souza Rosario (2004)
10.4158/EP10133.RA
Management of well-differentiated thyroid cancer in 2010: perspectives of a head and neck surgical oncologist.
Mark L. Urken (2010)
10.1210/jc.2001-011918
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Furio Pacini (2002)
10.1089/thy.2010.1632
The importance of pre- and postoperative laryngeal examination for thyroid surgery.
Gregory W. Randolph (2010)
10.1002/hon.955
The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Michael Lin (2011)
10.1007/s004230050111
Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma
J. Henry (1998)
10.3346/jkms.2012.27.9.1014
Preoperative Serum Thyroglobulin as a Useful Predictive Marker to Differentiate Follicular Thyroid Cancer from Benign Nodules in Indeterminate Nodules
Eun Kyung Lee (2012)
10.1530/EJE-12-0936
Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography.
Gilles Russ (2013)
10.1089/thy.2012.0227
Performance of elastography for the evaluation of thyroid nodules: a prospective study.
Ghobad Azizi (2013)
10.1089/thy.2011.0185
Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.
Dong Gyu Na (2012)
10.1089/10507250152741028
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
Wenli Wang (2001)
10.1186/1471-2482-9-12
Development of a clinical decision model for thyroid nodules
Alexander Stojadinovic (2009)
10.1089/THY.2009.1611
The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer
Douglas Van Nostrand (2009)
Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
Michael Lassmann (2004)
10.1089/thy.1997.7.277
Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma.
H. Murray Park (1997)
10.1210/jc.2006-1590
Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.
Giuseppe Costante (2007)
10.1210/jc.2009-2103
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.
Silvia Cantara (2010)
10.1088/0952-4746/26/2/001
Cancer consequences of the Chernobyl accident: 20 years on.
Elisabeth Cardis (2006)
10.1002/cncr.20081
Follicular thyroid carcinoma: histology and prognosis.
Alessandra D'Avanzo (2004)
10.1210/jc.2010-0161
Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial.
Iwao Sugitani (2010)
10.1016/j.jvir.2010.05.001
Ablation of skeletal metastases: current status.
A Nicholas Kurup (2010)
10.7863/jum.2006.25.12.1531
Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer.
Sanja Kusačić Kuna (2006)
10.1210/jc.2006-2311
18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm.
Jung Min Kim (2007)
10.1007/s00268-008-9711-9
Prospective Outcomes of Selective Lymph Node Dissection for Papillary Thyroid Carcinoma Based on Preoperative Ultrasonography
Iwao Sugitani (2008)
10.1530/EJE-08-0062
The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies.
Robbert B. T. Verkooijen (2008)
10.1056/NEJMoa075853
Motesanib diphosphate in progressive differentiated thyroid cancer.
Steven I Sherman (2008)
Sameday thyroidectomy: a review of practice patterns and outcomes for 1,168 procedures in New York State
CT Tuggle (2011)
Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large Page 350 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 18 4
M Shargorodsky (2006)
Persistent disease and recurrence in differentiated thyroid cancer patients with Page 328 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y
C Nascimento (2011)
10.1016/j.amjsurg.2008.04.017
Recurrent laryngeal nerve paralysis in patients with papillary thyroid carcinomas: evaluation and management of resulting vocal dysfunction.
Jong-Lyel Roh (2009)
10.1001/archotol.1994.01880350009002
Coexistent thyroid cancer and pregnancy.
Fred S. Herzon (1994)
Benign thyroid disease and vocal cord palsy.
R. T. J. Holl-Allen (1993)
10.1038/modpathol.2011.119
Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation
Ozgur Mete (2011)
Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Cheng-Hsiung Chen (2004)
10.1089/10507250150500694
Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.
Jong Ryeal Hahm (2001)
10.1159/000333274
BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance
Adebowale J Adeniran (2011)
10.1016/s1055-3207(18)30404-6
Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.
Stefan K. G. Grebe (1996)
10.1016/J.YSUR.2011.04.013
Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer
Thomas J. Fahey (2011)
10.1016/j.amjsurg.2003.08.015
Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients.
Guido M. Sclabas (2003)
10.1530/EJE-07-0896
Thyroid papillary microcarcinoma: a descriptive and meta-analysis study.
Elio Roti (2008)
Long term survival in DTC is worse after low-activity initial post-surgical I-131 therapy in both high and low risk patients
FA Verburg (2014)
10.1038/modpathol.2010.147
Familial thyroid cancer: a review
Vania Nosé (2011)
10.1002/14651858.cd001431.pub4
Decision aids for people facing health treatment or screening decisions.
Ann O'connor (2003)
10.1530/eje.1.02158
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
Furio Pacini (2006)
10.1515/CCLM.2009.216
Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma
Luca Giovanella (2009)
10.1530/EJE-10-0553
Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study.
Hanna Pelttari (2010)
10.1200/JCO.2011.41.2734
Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer.
Anna M Sawka (2012)
10.2214/ajr.178.3.1780699
Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma.
Bradley Lewis (2002)
10.1111/j.1365-2265.2007.02972.x
L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial.
Rébecca Leboeuf (2007)
10.1097/MNM.0b013e328340e74c
Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer
Amburanjan Santra (2011)
10.1210/jcem.87.3.8285
The effect of pregnancy on thyroid nodule formation.
Annie W. C. Kung (2002)
10.1016/j.otohns.2007.02.011
Prevalence and patterns of intraoperative nerve monitoring for thyroidectomy
Stefanie K Horne (2007)
10.1111/j.1365-2265.2008.03244.x
Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Luca Giovanella (2008)
10.1089/thy.2009.0406
Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
Eyal Robenshtok (2011)
10.1200/JCO.2008.18.2717
Phase II trial of sorafenib in metastatic thyroid cancer.
Richard T. Kloos (2009)
10.1097/00000478-198604000-00003
Risk Factors in Follicular Thyroid Carcinomas: A Retrospective Follow-up Study Covering a 14-Year Period with Emphasis on Morphological Findings
Winfried Lang (1986)
10.1038/nrendo.2011.142
Molecular genetics and diagnosis of thyroid cancer
Yuri E Nikiforov (2011)
10.1210/jcem.86.9.7824
Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules.
Maria Cristina Borba Braga (2001)
10.1097/00000478-198409000-00005
Poorly differentiated (“insular”) thyroid carcinoma: A reinterpretation of Langhans' “wuchernde Struma”
Maria Luisa Carcangiu (1984)
10.1097/01.rlu.0000227013.36421.ce
A Pragmatic Protocol for I-131 rhTSH-Stimulated Ablation Therapy in Patients With Renal Failure
Albert A. Driedger (2006)
10.1089/thy.2011.0429
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Mona M Sabra (2012)
10.1210/jc.2001-011762
Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis.
Marília Regina Costa Castro (2002)
10.1245/s10434-010-1017-0
Medullary Thyroid Cancer: Are Practice Patterns in the United States Discordant From American Thyroid Association Guidelines?
Babita Panigrahi (2010)
10.1159/000101753
Report of an International Survey of Molecular Genetic Testing Laboratories
Margaret M Mcgovern (2007)
10.1586/era.09.15
Stereotactic body radiation therapy for oligometastases
Simon S Lo (2009)
10.1001/archoto.2010.181
Surgery for papillary thyroid carcinoma: is lobectomy enough?
Abie H. Mendelsohn (2010)
10.5555/uri:pii:003960609290318T
Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy.
Jon A. van Heerden (1992)
10.1530/EJE-11-0466
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.
Maria Grazia Castagna (2011)
10.1210/jc.2007-1075
Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases.
Christine L H Snozek (2007)
10.1089/thy.2009.0274
The Bethesda System for Reporting Thyroid Cytopathology.
Edmund S Cibas (2009)
10.1089/thy.2013.0027
Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
Miriam N Lango (2013)
10.1089/thy.2009.0283
BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features.
Agnese Proietti (2010)
10.1002/hed.23829
Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
Sebastian M Jara (2015)
10.1177/0272989X9701700306
Patient Participation in Deciding Breast Cancer Treatment and Subsequent Quality of Life
Richard L. Street (1997)
External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent nonanaplastic non-medullary thyroid cancer
PB Romesser (2014)
Principles in thyroid surgery. In: Randolph GW (ed) Surgery of the Thyroid and Parathyroid Glands. 2nd edition
GW Randolph (2013)
Riskadapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156:1579–1588
A Ebina (2014)
10.1210/jc.2003-031341
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.
R. Elisei (2004)
10.1245/s10434-011-1833-x
Impact of Routine Unilateral Central Neck Dissection on Preablative and Postablative Stimulated Thyroglobulin Levels after Total Thyroidectomy in Papillary Thyroid Carcinoma
Brian H H Lang (2012)
10.1210/jc.2009-0869
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
R. Elisei (2009)
10.3413/Nukmed-0517-12-07
How reliable is secondary risk stratification with stimulated thyroglobulin in patients with differentiated thyroid carcinoma? Results from a retrospective study.
Johanna Berta Lemb (2013)
10.1210/jcem-62-2-410
Kinetic study of immunoreactive human thyroglobulin.
Motomori Izumi (1986)
10.1089/thy.2010.0308
Radioiodine therapy in patients with stage I differentiated thyroid cancer.
Jacqueline Jonklaas (2010)
10.1210/jcem.86.4.7390
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas.
M. O. Bernier (2001)
10.1177/000313480507100907
The Implication of Lymph Node Metastasis on Survival in Patients with Well-Differentiated Thyroid Cancer
Yale D. Podnos (2005)
10.1089/thy.2012.0051
Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma.
Kiminori Sugino (2012)
10.1067/msy.2003.71
Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area.
Ewald Kresnik (2003)
10.4158/EP.6.6.460
Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature.
Richard J Robbins (2000)
10.1210/er.2007-0007
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Mingzhao Xing (2007)
10.1097/SLA.0b013e3181f5ba51
Circulating Thyrotropin Receptor mRNA as a Novel Marker of Thyroid Cancer: Clinical Applications Learned From 1758 Samples
Mira Milas (2010)
10.1089/thy.2009.0208
Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms.
Carrie Lubitz (2010)
10.1007/s00423-008-0366-7
Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients
Anders Bergenfelz (2008)
10.1089/thy.2007.0269
Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography.
Eunhee Kim (2008)
Update on differentiated thyroid cancer
DP Momesso (2014)
Imageguided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma
JP Guenette (2013)
10.1007/s00268-009-0359-x
Three Distinctly Different Kinds of Papillary Thyroid Microcarcinoma should be Recognized: Our Treatment Strategies and Outcomes
Iwao Sugitani (2009)
10.4158/EP12420.OR
The diagnostic value of calcitonin measurement in wash-out fluid from fine-needle aspiration of thyroid nodules in the diagnosis of medullary thyroid cancer.
Chiara Diazzi (2013)
10.6004/JNCCN.2014.0068
International adaptations of NCCN Clinical Practice Guidelines in Oncology.
Robert W. Carlson (2014)
10.2310/JIM.0b013e318276deb4
A Novel Mass Spectrometry–Based Assay for the Accurate Measurement of Thyroglobulin From Patient Samples Containing Antithyroglobulin Autoantibodies
Nigel J. Clarke (2012)
10.1007/s00268-012-1547-7
Randomized Controlled Trial of Visualization versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve during Thyroidectomy
Marcin Barczyński (2012)
10.1089/thy.2010.0169
Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Yorihisa Orita (2011)
[Surgical treatment of advanced thyroid carcinoma with aero-digestive invasion].
Jun-heng Ge (2004)
10.1089/thy.2012.0099
One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy.
Rosália do Prado Padovani (2012)
Recurrent laryngeal nerve dysfunction ATA THYROID NODULE/DTC GUIDELINES 107 following carotid endarterectomy
AJ Curran (1997)
10.1089/thy.2009.0466
Salivary gland malignancy and radioiodine therapy for thyroid cancer.
Joanna Klubo-Gwiezdzinska (2010)
10.7326/0003-4819-101-1-25
Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings.
H. Gharib (1984)
Impact of initial surgical treatment on Page 295 of 411 T hy ro id D ow nl oa de d fr om o nl in e. lie be rt pu b. co m b y 91
M Duren (2000)
10.1007/s40618-014-0128-z
Evolution of benign thyroid nodules under levothyroxine non-suppressive therapy
Alessandro Puzziello (2014)
10.1210/jc.2011-3017
Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.
Ana Maria Chindriş (2012)
10.1007/BF03401308
Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treatment side effects and international differences in care
Rita Banach (2013)
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid
Vito Rodolico (2007)
10.2214/AJR.12.9901
Outcome of thyroid nodules characterized as atypia of undetermined significance or follicular lesion of undetermined significance and correlation with Ultrasound features and BRAF(V600E) mutation analysis.
Sun Hye Jeong (2013)
10.1001/jama.2011.1139
Use of radioactive iodine for thyroid cancer.
Megan R Haymart (2011)
10.1210/jc.2012-3160
Disease severity and radioactive iodine use for thyroid cancer.
Megan R Haymart (2013)
10.1007/s10549-011-1429-y
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer
Robert E. Coleman (2011)
10.3275/6471
Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
Arnoldo Piccardo (2010)
10.1016/j.jss.2013.12.022
Systematic review with meta-analysis of studies comparing intraoperative neuromonitoring of recurrent laryngeal nerves versus visualization alone during thyroidectomy.
Adolfo Pisanu (2014)
A piece of my mind. Moral wounds: complicated complications.
Shari Munch (2001)
10.1016/j.surg.2011.12.019
Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Brian H H Lang (2012)
10.1371/journal.pone.0001885
Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized Study
Hanna O Mäenpää (2008)
10.1159/000326358
Medullary Thyroid Carcinoma
Perikala Vijayananda Kumar (2000)
10.1016/j.clon.2004.08.009
The management of advanced thyroid cancer.
Patrick Christopher Wilson (2004)
10.1111/j.1365-2303.2010.00750.x
Thyroid fine needle aspiration cytology: a review of the National Cancer Institute state of the science symposium.
Lester J Layfield (2010)
10.5402/2012/816386
Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma
Kimberly M. Creach (2012)
10.1089/thy.2012.0567
Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome.
Jason S. Radowsky (2014)
10.1016/S0194-5998(95)70143-5
Management of the recurrent laryngeal nerve in suspected and proven thyroid cancer.
Sandor A Falk (1995)
Fineneedle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review
YY Tee (2007)
10.1097/00000658-200212000-00015
Prospective Functional Voice Assessment in Patients Undergoing Thyroid Surgery
Alexander Stojadinovic (2002)
Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important?
Clive S. Grant (1988)
Diagnostic 131-iodine whole-body scan 122 HAUGEN ET AL. may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment
F Pacini (2002)
Clinical experience with recombinant human
G Mariani (2000)
10.1089/thy.2009.0442
Papillary thyroid carcinoma with brain metastases: an unusual 10-year-survival case.
Elizabete Rosária de Miranda (2010)
10.1210/jc.2008-1931
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
S. Guerrero Bonnet (2009)
10.1210/jc.2011-2812
Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin.
Francesco Latrofa (2012)
10.1677/erc.1.00892
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.
Thera P. Links (2005)
10.1016/0002-9343(94)90321-2
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
Ernest L. Mazzaferri (1994)
10.1210/jc.2012-3539
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.
Ian Ganly (2013)
10.1148/radiology.215.3.r00jn07801
Importance of thyroid abnormalities detected at US screening: a 5-year follow-up.
Antti Brander (2000)
10.1002/hed.21504
Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer.
Brandon M. Barney (2011)
ATA THYROID NODULE/DTC GUIDELINES
JC Sisson (2011)
10.1002/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.0.CO;2-O
Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma
Chandrasekhar Bal (1996)
10.1097/01.mlg.0000154725.00787.00
The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma.
Zayna Nahas (2005)
10.1016/S0002-9610(97)00158-X
Differentiated thyroid cancer presenting initially with distant metastasis.
Ashok R Shaha (1997)
10.1097/MNM.0b013e328324b431
Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging
Wengen Chen (2009)
10.1002/jso.21385
Evolution in the surgical management of well-differentiated thyroid cancer or not: to dissect or not dissect the central lymph node compartment.
Martha A. Zeiger (2010)
10.1007/s00259-009-1315-6
No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer
Frederik Anton Verburg (2009)
10.1136/mp.56.3.162
Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer
Dimitris K. Grammatopoulos (2003)
10.1245/s10434-012-2288-4
Clinical and Ultrasonographic Findings Affecting Nondiagnostic Results upon the Second Fine Needle Aspiration for Thyroid Nodules
Yoon Seong Choi (2012)
10.1245/s10434-012-2380-9
Reoperative Lymph Node Dissection for Recurrent Papillary Thyroid Cancer and Effect on Serum Thyroglobulin
David T. Hughes (2012)
10.1089/thy.2010.0226
Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity.
Anna R. Laury (2011)
10.1177/0194599813481942
Clinical Significance of BRAF Mutation in Thyroid Papillary Cancer
Ignacio Javier Fernandez (2013)
10.1210/jc.2009-0247
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
Yuri E Nikiforov (2009)
10.3348/kjr.2007.8.3.192
Evaluating the Degree of Conformity of Papillary Carcinoma and Follicular Carcinoma to the Reported Ultrasonographic Findings of Malignant Thyroid Tumor
S. Jeh (2007)
10.1007/s00259-008-0912-0
Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans
Eun-kyung Park (2008)
10.1046/j.1365-2265.2003.01735.x
Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma.
Maurice J H M Pluijmen (2003)
10.1089/thy.2000.10.261
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients.
Anastassios G. Pittas (2000)
10.1111/j.1365-2265.2005.02406.x
Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology?
Carlo Cappelli (2005)
10.1097/00005537-200403000-00002
Safety of modified radical neck dissection for differentiated thyroid carcinoma.
Michael Elliot Kupferman (2004)
10.1089/thy.1996.6.493
Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing.
Valeria C. C. Guimaraes (1996)



This paper is referenced by
10.1371/journal.pone.0205293
The relationship between resting energy expenditure and thyroid hormones in response to short-term weight loss in severe obesity
Paolo Marzullo (2018)
10.14366/usg.18050
Is thyroid nodule location associated with malignancy risk?
Valeria Ramundo (2019)
10.1530/EJE-18-0078
TIRADS score is of limited clinical value for risk stratification of indeterminate cytological results.
Ernesto Chaigneau (2018)
10.1007/s12020-018-1739-5
Intraoperative intermittent neuromonitoring of inferior laryngeal nerve and staged thyroidectomy: our experience
Ottavio Cavicchi (2018)
10.3413/Nukmed-0981-18-06
Fine-needle aspiration biopsies of thyroid nodules.
Michael Cordes (2018)
10.1038/s41574-018-0068-3
Follow-up of differentiated thyroid cancer – what should (and what should not) be done
Livia Lamartina (2018)
10.1002/hed.25049
Computer‐aided system for diagnosing thyroid nodules on ultrasound: A comparison with radiologist‐based clinical assessments
Luying Gao (2018)
10.1016/j.jacr.2017.01.046
ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee.
Franklin N. Tessler (2017)
10.1007/s40618-018-0884-2
Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies
Furio Pacini (2018)
10.1002/hed.25068
Novel method to save the parathyroid gland during thyroidectomy: Subcapsular saline injection
June Young Choi (2018)
10.1177/2473974X18788545
Efficacy of 18F-fluorodeoxyglucose PET/CT for Detecting Lymph Node Metastasis in Papillary Thyroid Carcinoma
Dong Won Lee (2018)
10.1186/s12957-018-1370-1
Single metastasis of myxoid liposarcoma from the thigh to thyroid gland: a case report
Hiroshi Urakawa (2018)
10.1016/J.CIRENG.2018.05.010
BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?
Maite Domínguez Ayala (2018)
10.1007/s12020-017-1382-6
Performance of Italian Consensus for the Classification and Reporting of Thyroid Cytology (ICCRTC) in discriminating indeterminate lesions at low and high risk of malignancy. A systematic review and meta-analysis
Pierpaolo Trimboli (2017)
10.1210/jc.2017-01708
Predictive Value of Malignancy of Thyroid Nodule Ultrasound Classification Systems: A Prospective Study
Agnese Persichetti (2018)
10.1001/jamaoto.2017.1442
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance
Robert Michael Tuttle (2017)
10.1016/j.oraloncology.2017.09.004
The incidence and management of non-head and neck incidentalomas for the head and neck surgeon.
Axel Sahovaler (2017)
10.1007/s12022-017-9502-7
Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review
Francesca Ambrosi (2017)
10.1136/bmjopen-2018-025820
Public perceptions of changing the terminology for low-risk thyroid cancer: a qualitative focus group study
Brooke Nickel (2019)
10.5772/INTECHOPEN.70128
Thyroid Cancers: Considerations, Classifications, and Managements
Mohammad Hossein Khosravi (2017)
10.1016/j.joto.2017.10.001
Does the use of recombinant TSH in preparation for I-131 scintigraphy scan affect hearing function?
Mehtap Doğan (2018)
10.1016/j.surg.2017.07.011
Dr Google: The readability and accuracy of patient education websites for Graves' disease treatment
Amanda C. Purdy (2017)
10.1089/CT.2017;29.271-273
Extrathyroidal Extension Predicts Decreased Survival in Thyroid Cancer Patients
J LivhitsMasha (2017)
10.1210/jc.2017-00255
Population-Based Assessment of Complications Following Surgery for Thyroid Cancer
Maria Papaleontiou (2017)
10.1373/clinchem.2016.269456
Harmonization of Serum Thyroid-Stimulating Hormone Measurements Paves the Way for the Adoption of a More Uniform Reference Interval.
Linda M. Thienpont (2017)
10.1097/MD.0000000000007512
Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
Jeonghoon Ha (2017)
10.1136/bcr-2017-219747
Insular carcinoma arising on a background of follicular carcinoma, thyrolipomatosis and amyloid goitre
Tze Ling Loh (2017)
10.1002/jso.24740
Prognostic factors for recurrence of locally advanced differentiated thyroid cancer
Bo-young Kim (2017)
10.1016/J.MEDCLI.2017.01.007
Carcinoma medular de tiroides en un paciente con síndrome de Birt-Hogg-Dubé
Leire Pérez García (2017)
10.1089/CT.2017;29.468-471
Second Radioactive Iodine Treatment Alone Is of Little Benefit in Treating Patients with Locoregional Persistent Differentiated Thyroid Carcinoma Who Previously Have Been Treated with Total Thyroidectomy and Ablative Radioactive Iodine
H EmersonCharles (2017)
10.1089/CT.2017;29.437-439
Multifocality Is Not an Independent Risk Factor for Recurrence of Papillary Thyroid Cancer
M HershmanJerome (2017)
10.1097/MNM.0000000000000777
Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma
Xinyu Wu (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar